At the Serono Symposia International Foundation (SSIF), we believe that it is more important than ever to ensure that the very best independent continuing medical education (CME) is available to clinicians, scientists, and researchers. Every day across the world, new research findings and improvements in diagnosis and treatment mean new opportunities to improve outcomes for patients.
This booklet focuses on one very important strand of our work in CME: reproductive medicine. It clearly exemplifies the approach that SSIF takes to all of the areas we cover and the many events we hold each year, sharing the knowledge and insights of internationally renowned experts with audiences worldwide through live educational activities and, increasingly, online. In September 2013, scientists and clinicians in the field of human reproduction participated in a groundbreaking conference held in Florence, Italy. Over the course of two days, authors of the 10 most cited, viewed, or downloaded research articles in the field presented their papers. Each author was confronted by a "challenger," after which participants discussed the paper's findings and significance. The goal: to advance rigorous science in a field dominated by small-scale studies and trial and error. "Everyone is aware of the clinical relevance of assisted reproduction technology [ART] ," said Carlos Simón, professor of obstetrics and gynecology at the University of Valencia, Spain, and a conference scientific organizer. "We need to increase our scientific relevance."
The Top Ten in Reproductive Medicine
In 2009, the World Health Organization officially recognized infertility as a disease. Not all countries, however, have followed suit. Consequently, largescale funding of fertility treatments has been scarce. Regulation differs among countries, making adoption of standard practices difficult. And on the basic research front, strict embryo protection laws in some countries restrict studies on human embryos. "If you look at all the things we do in the clinic, I would bet half of them have never been proven efficient in multicenter trials," said Hans Evers, a professor in the department of obstetrics and gynecology at Maastricht University Medical Centre in Maastricht, The Netherlands. Intracytoplasmic Sperm Injection (ICSI) whereby sperm is injected directly into an egg, for example, is now being used to treat unexplained infertility in about half of all treatment cycles, said Evers. "But no one has ever shown that ICSI is necessary in unexplained infertility."
ICSI was an advance initially developed to help men with poor sperm quality become fathers when traditional in vitro fertilization failed. The past 10 years have seen additional advances in technology aimed at helping greater numbers of people become parents, too. Several of the most promising of these were discussed at the conference. Embryo cryopreservation, for example, may make in vitro fertilization (IVF) safer and less stressful by enabling a woman to undergo ovarian stimulation only once to retrieve eggs (See Cobo, page 25). And embryo selection technology that can distinguish healthy embryos from unhealthy ones promises to raise success rates. Further in the future it will be possible to diagnose any number of gene mutations in an embryo and harvest eggs from ovarian stem cells so that older couples can have biological children (see Legro, page 35 and Lamb, page 40).
However, the best application of these technologies should be debated before they come into widespread use, said Evers. Moreover, some technologies pose ethical questions that require societal input. For example, while diagnostic tests can detect the presence of a gene, the tests may be meaningless since genes don't predict with 100% certainty whether a person will actually develop a disease. Also, if women beyond normal reproductive age can indeed one day have biological children, then how old is too old? "You have to think about these things before the possibility arises," said Evers.
To start addressing these issues, The "Top Ten in Reproductive Medicine" conference highlighted the best papers as an example of how research into human reproduction and infertility should be done. The format, inspired by Simón and developed by the Serono Symposia International Foundation (SSIF), was the first of its kind in the field. By discussing each paper-five clinical and five basic research-at length, conference organizers hope to promote good clinical practice that comes from adopting technologies and practices that are backed by strong scientific evidence and that have been validated by ethical debate.
ASSiSTeD RePRODuCTiOn TeChnOlOgieS:
We CAn DO BeTTeR IVF has changed little since Robert Edwards and Patrick Steptoe introduced the technique over 35 years ago. While there have been advances in the field, such as the ability to freeze sperm or eggs and test embryos for specific genetic abnormalities, the process remains much the same: Fertilize egg with sperm, transfer the resulting embryo into a woman's uterus, and hope for a full-term pregnancy. The technique has brought five million babies into the world and fulfilled the longing of parenthood for couples struggling with infertility.
But IVF has a downside. The drugs given to stimulate the ovaries to produce multiple eggs can overstimulate the ovaries and land women in the hospital, when the clinical condition is particularly risky. The procedure is stressful, primarily because it's hard to predict whether it will work. Depending on the age of the eggs, the clinic, and the procedure used, any embryo transfer cycle has between a 25% and 40% chance of resulting in a baby. With the odds in favor of failure, doctors have typically transferred more than one embryo to boost the chance of success. While the rate of triplets and higher order births has come down drastically, the number of twins born from reproductive technologies remains at about 30% of all ART births in the U.S. A twin or multiple pregnancy has long been known to raise the risk of harm to both mother and babies. Maternal complications include increased rates of pre-eclampsia, gestational diabetes, and preterm labor. Risks for babies include low birth weight and prematurity as well as a higher risk of long-term disability and death as compared with singleton pregnancies.
WiTh neW TeChnOlOgieS, SuCCeSS iS MORe likely
At the conference, Christina Bergh from the Sahlgrenska University Hospital in Gothenburg, Sweden presented her 2004 paper that for the first time provided evidence that transferring a single embryo yields almost the same birth rate as transferring two in women under age 36 (see page 23). Bergh's paper was the first clinical paper presented and set the backdrop for the presentations that followed. It began with the question: How can we treat infertility and inflict the least harm? The paper was among the most highly viewed over the last 10 years, primarily because it was published when rates of multiple births using ART were much higher than they are today. Since the paper was published, single embryo transfer (SET) has been widely adopted, particularly in Northern Europe. In Sweden, doctors use SET in 75% to 80% of all IVF cycles in women of any age, said Bergh. But there remain several countries in which it hasn't caught on, she added, and this is likely because of differences in reimbursement practices for reproductive procedures.
Bergh presented additional data showing that SET works well in women up to age 42. Additionally, she studied children born from IVF procedures and showed that at the same time, the rate of complications had also decreased drastically. "Her work has really pushed the SET idea worldwide," said her challenger Robert Fischer, medical director of Fertility Center in Hamburg, Germany and SSIF Scientific Committee Member. However, Swedish statistics may not hold for other populations, said a clinician from the audience. Patients in Scandinavia opt for IVF treatments much more quickly than patients in southern Europe, he added. Consequently, IVF patients in southern Europe tend to be older and have poorer outcomes. In such a setting, SET may not be as successful. Another participant pointed out that for SET to really take off, success rates would need to be much higher.
eMBRyO SeleCTiOn AnD FReezing
One way to raise success rates would be to distinguish good embryos from bad ones. Enter Richard Scott's 2010 paper on detecting aneuploidy in an embryo using whole genome amplification and single nucleotide polymorphism arrays (see page 27). Scott showed that the technology can distinguish abnormal from normal embryos with a 4% error rate. Since publication, additional data shows that the error rate is actually only around 1%, said Scott, director of reproductive science at Robert Wood Johnson Medical School in Basking Ridge New Jersey. The paper was the first of a series of four that together show that the technology gives clinically meaningful results, Scott said.
For example, in one study, Scott and his colleagues biopsied embryos and transferred them back into women as part of their infertility care, before they knew the biopsy results. Once they determined the success or failure of the procedure, they then compared the biopsy 
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analysis data with birth outcomes and showed that the DNA array technology could detect, with 99% accuracy, an abnormal embryo that was unlikely to develop into a baby. Another study showed that selecting embryos using this technology does indeed yield higher birth rates. The predictive power of the technology is so great that the Reproductive Medicine Associates of New Jersey fertility clinic of which Scott is the director now performs SET using the diagnostic technology in 70% of all IVF cycles, he said. The clinic also offers the diagnostic service to other clinics.
The technology isn't easy to implement, however, and is expensive compared with other technologies on the market, challenger Carlos Simón pointed out, and no one has yet demonstrated that the array technology yields better clinical outcomes as compared with those alternatives that are cheaper and easier to use. Discussion also raised the point that array technologies may be rendered obsolete in the near future by next generation technologies that can sequence genes faster and cheaper. In fact, there are already companies selling tests that purport to predict the chance of a child inheriting certain traits based on sequencing specific parental genes. Adapting such tests to screen embryos for specific traits would be a simple task-the prospect of which has raised more than a few eyebrows. Nevertheless, technologies to parse normal embryos from abnormal ones are a boon to the field because they raise success rates. Scott's clinic is seeing pregnancy rates of greater than 50%, he said, and preliminary data suggests that embryo selection is bringing preterm births rates down to a level on par with the general population.
Microarrays aren't the only promising embryo selection technology available. During the meeting Renee Reijo Pera, a professor in the department of obstetrics and gynecology at Stanford University School of Medicine, presented her 2010 paper on noninvasive imaging of human embryos (see page 15). The paper showed that time-lapse image analysis of two-day old zygotes together with gene expression profiling could with 93% accuracy predict which embryos would develop to the blastocyst stage. Three parameters captured by imaging appeared to be the most predictive: duration of the first cell division, the time interval between the end of first mitosis and initiation of the second (mitosis is the replication of chromosomes that precedes cell division), and the time interval between the second and third mitoses. "This is an example of out of the box thinking," said challenger Simón. However, he pointed out there is a lack of randomized clinical trial data showing that embryo selection using this technology results in higher birth rates. Discussion also raised the issue of a lack of standards, with groups trying to replicate the results using different measurement techniques.
In yet another advance, embryo freezing would make IVF safer and finally make it possible for young women suffering from ovarian cancer and premature ovarian failure to have families later in life. Ana Cobo, an embryologist from the Infertility Institute in Valencia, presented her 2008 paper comparing fresh eggs to those cryopreserved by Cryotop-a commercially available method to vitrify human tissues (see page 25) . Vitrification is the conversion of a water containing solution to a glass-like solid that is free from the ice crystals normally formed during freezing. She and her colleagues found that cryopreserved eggs were just as readily fertilized and able to develop into blastocysts as fresh ones. Cobo also presented recent data showing that the pregnancy rate from cryopreserved embryos is similar to that of fresh embryos.
"The paper got a lot of interest because oocytes have been extremely difficult to freeze," said challenger Evers. "The Cobo study showed for the first time in a large number of patients that you can do it and have good outcomes." Moreover, embryo cryopreservation if broadly implemented might reduce the need to put back more than one embryo, Evers added, because you can freeze several and put them back in subsequent cycles if a woman doesn't become pregnant. It may even enhance pregnancy rates because the endometrial environment appears to be "more friendly" during normal cycles as compared to drug stimulated cycles, he added.
exPAnDing The BOunDARieS OF TReATMenT
In the future, there may be no limit to the age at which a woman is able to bear children, according to Jonathan Tilly, professor and chair of biology at Northeastern University. His 2012 paper provided evidence that human ovarian tissue contains pools of ovarian stem cells that develop into human oocytes-confirming what researchers have found in other animals and overturning the long-held dogma positing that women are born with a fixed number of eggs that are never replenished (see page 10). Tilly first shocked the field in 2004 when he and his colleagues extracted ovarian stem cells from female mice for the first time.
In the recent paper, Tilly and his colleagues developed a more sensitive method to identify and collect mouse ovarian stem cells. Once the team confirmed that it had isolated the mouse ovarian stem cells by this new method, it repeated the technique with frozen ovaries donated from sex-reassignment patients. When cultured, the retrieved oogonial stem cells (OSCs) turned into immature oocytes. The team then tagged the cells with green fluorescent protein to trace them and injected them into pieces of human ovarian tissue, which were then transplanted into mice. After about two weeks, the OSCs had differentiated into green-glowing cells that by all measures appeared to be human oocytes.
"This was one of the most astonishing papers published in 2012," said challenger Felipe Vilella from the Valencia Institute of Infertility in Spain. However, no one has yet shown that the human-derived OSCs can be fertilized to form an embryo, Vilella said, and no one knows whether any offspring would be healthy. Although studies on animal derived OSCs have produced offspring, no data on the health of the offspring has been provided, said Vilella. Nevertheless, research on monkeys and ultimately humans is in the planning stages, Tilly said. If the research pans out, it would give women with ovarian cancer the chance to have children later in life. It would also open the possibility that women well into their 50's and even older could bear biological children-the ethics of which "are not for me to decide," concluded Tilly.
Vilella's questions about the health of offspring raised another important point of debate: whether any of the procedures used in IVF, currently or in the future, might unwittingly be harming the resulting offspring. At the meeting, Michael Skinner, director of the center for reproductive biology at Washington State University in Pullman Washington, presented his serendipitous finding revealed in his 2005 paper on the epigenetic transgenerational effects of endocrine disruptor chemicals on rodents (see page 18). If a pregnant female rodent was exposed to endocrine disrupting chemicals during a window when the fetus's sex cells were developing, the chemical exposure caused epigenetic alterations-changes in methylation patterns in the genome-in sperm. These alterations were passed down through at least four generations and reduced male fertility. Skinner has since tested several additional chemicals and found the same or similar effects on sperm, and that these epigenetic changes can cause disease in subsequent generations. In one study [Reprod. Toxicol. 34:708 (2012)], for example, Skinner showed that pregnant female rats exposed to the pesticide mixture DEET-commonly found in insect repellants-gave birth to pups with higher rates of disease that included pubertal abnormalities, testis disease, and ovarian disease. Disease susceptibility was predominantly passed via males and persisted for three generations.
A similar issue has been raised before in regard to IVF techniques. Could the egg or culture media be exerting an effect on the epigenetics of the developing embryo? To date, rigorous studies
have not yet been done to answer this question. But the debate certainly generated enough interest and ideas for future studies.
WRAP uP
After the meeting, participants lauded the challenge and debate format. "From my perspective this type of format should be broadly applied," said Tilly. "It's an awesome idea," Scott added, "and I'm not prone to hyperbole." Some, however expressed a desire for more probing questions. "We were all being a little too nice," Reijo Pera said. But everyone agreed that in contrast to large conferences where there is little time for discussion and questions, this one enabled much more opportunity to learn. Such feedback will be important in organizing the second Top Ten in reproductive medicine conference, which is already in the works. According to Simón, the next one will likely take place in four years-enough time to publish new papers and to measure whether the first conference had an impact on spreading ideas and improving the way research in reproductive medicine is done. The 1960's through the 1970's was a period of great change in reproductive medicine. Knowledge about reproduction increased dramatically. Before in vitro fertilization (IVF), gynecology had little more to offer infertile couples than making a diagnosis and offering tender, loving care (1) . When the efforts of the two pioneers, Robert G. Edwards and Patrick C. Steptoe, resulted in the birth of the first IVF baby in 1978, the world slowly started to understand the insurgency that these two icons had caused in the medical field. Not without open antagonism from some, Edwards became acclaimed as the father of IVF and his discoveries were belatedly recognized by the awarding of the Nobel Prize in Physiology or Medicine in 2010. By then, several millions of babies had been conceived through IVF and the term assisted reproductive technology (ART) was coined to include other procedures that improved infertility treatment. Edwards' work laid the foundation for further exciting developments in reproductive medicine, such as preimplantation genetic diagnosis (PGD).
ART is focused on bringing better gametes into close proximity in order to generate a viable embryo, which can then be placed in a receptive endometrium to generate a healthy, full-term pregnancy. The greatest progress has been made in improving embryo viability and increasing implantation rates which, unintentionally, has led to the main drawback-the unacceptably high incidence of multiple births. The rate of multiples has been substantially reduced by the introduction of elective single embryo
HISTORY AND PERSPECTIVE
Reproductive Medicine Before and After the Nobel J.L.H. Evers and Antonio Pellicer transfer (eSET), one of the few ART developments that has been introduced based on robust clinical data (2) . Regulatory initiatives for eSET approval have followed around the world. However, there is still much to be done before eSET is universally accepted.
An ART process begins with controlled ovarian stimulation (COS), the manipulation of the reproductive physiology to generate several mature oocytes simultaneously in a single cycle. In the early days of ART, this was a necessary functional step because the techniques for fertilization and culture were poor, so several eggs needed to be fertilized to obtain just a few viable embryos. Today, the procedures used in ART labs are much more sophisticated, so there is a diminished need for aggressive COS. The field is now moving towards more gentle and patient-friendly stimulation protocols which will produce only an adequate number of embryos, and no more (3).
in ViTRO SCReening
Several methods for performing genetic screens on embryos, both invasive and noninvasive, are in the research pipeline right now. After some initial controversy regarding the biopsy and screening of embryos for a limited number of chromosomes, the introduction of more accurate technologies that provide more detailed information on all chromosomes-such as single nucleotide polymorphism arrays-is looking promising, especially for use in older patients (4) . In vitro embryo observation utilizing time-lapse technology (5) , and the analysis of proteins and metabolites consumed and secreted by the developing embryo in culture, are other noninvasive methods that hold promise.
The same molecular techniques are applied during PGD in order to detect those embryos carrying particular disease-associated mutations. The list of diseases is steadily increasing and in the future it will become possible to diagnose multiple disorders simultaneously in a single embryo, shifting the frontiers in human health care. These advances will, however, also raise important ethical questions that will need to be addressed (6) , such as how to contend with the partial expression or limited penetrance of certain diseases that might only manifest in later life.
CRyOPReSeRVATiOn
Although the failure of embryo implantation was a concern in the early days of IVF and a valid justification for the use of multiple embryos, the problem was compounded by the poor performance of embryo cryopreservation techniques. However, vitrification-introduced as a method of cryopreservation in the 1980'scompletely changed the field for both embryo and oocyte freezing (7) . Today, survival rates after freezing/thawing of human oocytes and embryos are greater than 90%, bringing about new possibilities for ART, while also reducing the need for ethically questionable selective abortions.
Vitrification has also been applied as a means to preserve fertility in young women with cancer, allowing for the freezing of oocytes prior to chemotherapy or radiation treatment. Meanwhile, fertility preservation has more recently been introduced to avoid the deleterious effects of aging on the oocytes ('social freezing'). Since age correlates positively with aneuploidies, an increasing number of women are requesting oocyte freezing before age 38 in an attempt to abrogate this effect (8) .
Two other complications of COS deserve our attention: an altered endometrial receptivity that decreases the chance of implantation, and the development of ovarian hyperstimulation syndrome (OHSS), a rare but potentially life-threatening condition. A new two-step ART approach that involves the implantation of previously frozen embryos in subsequent natural cycles will potentially lead to a safer and more patient-friendly ART approach with fewer complications (9, 10) .
The enDOMeTRiAl enViROnMenT
Most attention in ART is focused on the embryo, but endometrial receptivity is an issue that is often neglected, predominantly because insufficient methods exist to ascertain the functional status of the uterine lining. In today's ˈ omics era, however, new tools are coming to the fore that will allow the best embryo(s) to be placed in a fully receptive endometrium (11) .
Despite numerous advances in reproductive technologies, we still have very limited possibilities for addressing the main cause of infertility, namely the woman's age. The next two decades will see research in developing methods to rejuvenate oocytes by exploring the cellular and molecular hallmarks of aging and attempting to at least partially reverse them (12) . Similarly, the creation of gametes by cell reprogramming could be another source of healthy oocytes (and spermatozoa), an advance that will certainly change our perspective on infertility in the coming years (13, 14) .
Most of these potential advancements in ART are still based on small, observational clinical "proof-of-concept" studies. They demand to be followed up with more comprehensive, multicenter randomized clinical trials. Subfertility couples belong to a vulnerable group and should not be exploited (15) . We should provide them with dedicated care and evidence-based treatment. During the next decade, the medical establishment needs to provide more robust evidence for the value and integrity of the treatments currently offered to patients. As Robert Edwards, our very own Nobel Laureate stated: "the legacy to future generations is a matter of life" (16) . 
Germline Stem Cells in Adult Mammalian Ovaries
Dori C. Woods and Jonathan L. Tilly inTRODuCTiOn Until recently, a decades-old belief in the field of mammalian reproductive biology was that females are born with a finite endowment of oocytes, termed the 'ovarian reserve,' which is progressively depleted throughout life by either ovulation or atresia (1) . Once exhausted, the ovaries cease to function. In women, this event heralds the onset of menopause (2) . Although the traditional explanation for the cessation of ovarian function-namely that a woman simply runs out of oocytes, fits the model of the ovarian reserve being set forth as a nonrenewable resource at birth, a number of recent studies indicate that this paradigm is probably incorrect. In its place has emerged a model that aligns gametogenesis in mammals more closely with that observed in non-mammalian species, in that adult ovaries actively support formation of new oocytes and follicles (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) . The underlying foundation of this major paradigm shift is rooted in the development of detailed methods for the isolation and characterization of a rare population of mitotically active germ cells from adult ovaries termed female germline stem cells (fGSCs) or oogonial stem cells (OSCs) (4, 6, 8, 12) . Once isolated, these cells can be stably propagated in vitro for months without loss of their ability to differentiate into oocytes following either defined culture in vitro or transplantation into ovarian tissue in vivo (4, 5, 7, 8, 14) . In mice, oocytes formed from transplanted OSCs complete maturation to the metaphase-II stage of development, and these eggs can be fertilized to produce viable embryos and offspring (4, 7, 8, 12) .
While intraovarian transplantation models clearly show that mammalian OSCs are capable of generating fully functional eggs, the role of these cells, if any, in adult ovaries under normal physiological conditions has not yet been reported. In non-mammalian vertebrates, such as the teleost Medaka (Oryzias latipes), genetic-lineage-tracing approaches have been successfully employed to show that fGSCs actively contribute to the adult oocyte pool used for reproduction (15) . Development and analysis of similar genetic models in mice, which are currently under investigation in the Tilly laboratory, should provide a means to map the rates of new oocyte formation during postnatal life, and the contribution of these oocytes to offspring production. In addition, the ability to track a 'marked' pool of oocytes formed at a specific point in life will facilitate studies of in vivo oocyte lifespan to determine how long a given oocyte, once generated, persists in adult ovaries. This information will help elucidate if the quality of eggs deteriorates in women with age simply because all of the oocytes have been sitting around for decades accumulating damage, or if the decline in egg quality is instead tied to a progressive impairment in the ability of OSCs to generate competent oocytes with age, as is the case in the aging Drosophila ovary (16) .
ChARACTeRizATiOn OF MOuSe AnD huMAn OSCS
Although the beginnings of contemporary evidence for the existence of OSCs and postnatal oogenesis date back nearly a decade (3), the recent development of protocols that allow for the enrichment or purification of OSCs from adult ovaries has greatly accelerated research in this area (4, 6, 8, 12) . Building on earlier observations that mouse OSCs expose the C-terminus of the germ cell-specific protein, Ddx4 [DEAD box polypeptide 4; also commonly referred to as Vasa or Mouse vasa homolog (Mvh)] on the outer cell surface (4), we developed and validated an antibody-based fluorescence-activated cell sorting (FACS) approach that purifies OSCs based on detection of this extracellular epitope of Ddx4 (extracellular Ddx4-or ecDdx4-positive cells) (8, 12, 13) . The reason why Ddx4 is exposed on the surface of OSCs but is completely internalized in oocytes is unknown, but may be related to movement of the protein from a potentially sequestered transmembrane location to a more functionally active position in the cytoplasm as primitive germ cells undergo meiotic differentiation (13) . Of note, similar OSC isolation strategies have been reported using antibodies against the externalized domain of the primitive germ cell marker, Ifitm3 (interferon-induced transmembrane protein 3; also referred to as Fragilis) (6, 12) .
Following isolation and expansion of OSCs in vitro, the cells can be genetically modified to express a traceable gene (such as green fluorescent protein, GFP) and returned to the ovaries of recipient wild type mice where they actively undergo differentiation into oocytes that mature, ovulate, and fertilize to produce viable embryos and offspring (4, 7, 8, 12) . Although this type of cell fate-tracking experiment is not feasible in humans, we have successfully employed a mouse xenograft model to establish the oocyte-forming capabilities of human OSCs, expressing GFP, in adult human ovarian tissue in an in vivo environment (8, 12) . The ensuing observations that human OSCs form what appear to be meiotically arrested oocytes [positive for expression of Y-Box protein 2 (YBX2), which is specifically expressed in germ cells at the diplotene stage of meiosis (17, 18) ] contained in follicles within one to two weeks of grafting not only provides definitive evidence that adult human ovaries are fully capable of supporting oogenesis and folliculogenesis, but also that oocyte and follicle formation from purified OSCs returned to their natural environment are events that can occur in a fairly rapid timeframe (8, 12) .
COnTROVeRSiAl neW FinDingS?
Although independent verification of the existence of OSCs in adult mouse ovaries is now available from several labs (4) (5) (6) (7) (8) (12) (13) (14) , two new studies-both based on circumstantial negative findings with mice-claim otherwise despite the fact that neither study actually attempted to reproduce what we and others have done or to isolate OSCs from mouse ovaries using published protocols employed successfully by us and others. The first of these, from Liu and colleagues, relied entirely on a transgenic reporter mouse generated by crossing Ddx4-Cre mice with Rosa26 rbw/+ mice, on the assumption that OSCs could be specifically tracked due to Ddx4-driven Cre activation in these cells (as would be the case with all germ cells, irrespective of their differentiation status) (19) . Unfortunately, an absence of many key control experiments, discussed in detail recently (12) , precludes any clear interpretation of the findings. In fact, in as-yet unpublished studies we have since evaluated ovaries from the same genetic mouse line, and combined this approach with our FACS-based protocol for OSC isolation, to highlight the erroneous nature of their primary conclusion that, in contrast to substantial evidence from us and others (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) (13) (14) 20) , mitotically active germ cells do not exist in postnatal mouse ovaries.
The second paper relies heavily on two key assumptions (21) . The first is that oogenesis in embryonic and adult ovaries is accomplished through identical processes. In fetal ovaries, primordial germ cells proliferate and form cyst-like clusters prior to meiosis (22) . Upon meiotic commitment, the cyst-like clusters associate with somatic cells, forming the ovigerous cords that will break down shortly after birth to produce the initial primordial follicle pool (23, 24) . In this new study, Lei and Spradling propose a model, with no supporting data, that relies on formation of germ cell cysts as an indispensable step in postnatal oogenesis as well. When they failed to observe evidence of cyst-like germ cell clusters in adult mouse ovaries, the authors concluded that oogenesis is not occurring (21) . Another assumption relates to the "lineage tracing model" used, in which both Cre-recombinase and estrogen receptor are expressed in essentially all cells of the mice under study. Short-term induction with Tamoxifen excises a stop-cassette located within a Rosa26-yellow fluorescent protein (YFP) transgene, yielding indiscriminate labeling in which all cell types are 'marked' with YFP at very low frequency (1%-2%). Since all germ cells, including OSCs and oocytes, express YFP at equivalent frequencies, it is impossible to discern if any labeled oocytes originated from labeled OSCs or if any unlabeled oocytes originated from unlabeled OSCs. In fact, the authors acknowledge identification of "a few germ cells at a prefollicular state of development," but do not discuss the meaning of such findings (21) . Since oocytes are incapable of surviving in ovaries unless surrounded by granulosa cells as follicles, the rare "prefollicular" germ cells identified by Lei and Spradling are likely OSCs or their immediate progeny.
Whatever the case, assuming 2% of OSCs are YFP labeled in their Figure 1 . Assessment of human oogenesis using adult ovary-derived oogonial stem cells (OSCs). Ovarian cortical tissue from women is dissociated into single cell suspension, and OSCs are isolated by FACS using an antibody targeting the extracellular domain of DDX4 (ecDDX4) (8, 12) . Purified OSCs are established in culture and expanded ex vivo to assess egg maturation potential or the rate of oogenesis. To evaluate egg formation, OSCs are transformed to express a reporter (i.e., GFP) and directly injected into human ovarian cortical strips, which are then cultured in vitro to monitor formation of GFP-expressing oocytes contained in follicles. Growing follicles with GFP-positive oocytes are dissected and cultured further to obtain oocytes that can be in vitro-matured to the metaphase-II (egg) stage of development (28) (29) (30) . To evaluate oogenesis rates, human OSCs are transformed to express DsRed under control of the promoter of the Stra8 gene, which is activated during meiotic commitment in germ cells. The cells are then screened for factors that activate DsRed expression. Positive hits, representing candidate meiotic (oogenic) activators, are then assessed with a secondary screen in which the number of oocytes formed in vitro by a fixed number of OSCs per well exposed to the candidate factor is determined (12, 14) . If a given factor is identified as a positive hit in both assays (increased DsRed expression and oogenesis in vitro), it is then tested for its ability to increase oocyte-containing primordial follicle numbers in adult mouse ovaries in vivo.
model, one would expect the ratio of labeled and unlabeled oocytes comprising the primordial follicle pool to remain constant over time since a fixed proportion of labeled and unlabeled oocytes would be constantly entering the pool through de novo oogenesis from a chimeric population of OSCs and subsequently exiting the pool through follicle growth activation. This is exactly what Lei and Spradling observe (21) . It bears mention that a toxicity model was also employed to assess if OSC activation and follicle renewal in postnatal ovaries occurs in response to damage. When such evidence was not produced, these negative findings were offered as further proof that OSCs do not exist. Surprisingly, however, the cytotoxic drug used was busulfan, which is a widely known GSC toxicant (3, (25) (26) (27) . Accordingly, it is unclear why one would expect to find damage-induced activation of a population of cells that are killed by the agent used to 'activate' them.
nexT STePS AnD huMAn heAlTh iMPliCATiOnS As work with laboratory animal models continues to fill in key gaps in our understanding of mammalian OSCs, the discovery of oocyte progenitor cells in human ovaries opens up many opportunities for their utilization, some from the perspective of the clinical management of infertility and others from that of basic biomedical discovery (8, 9) . Given the remarkable similarities between mouse and human OSCs, and in particular the ability of OSCs from both species to participate in new oocyte and follicle formation when delivered back into adult ovarian tissue (8, 12) , it would stand to reason that, as observed in mice (4, 7, 8, 12) , human OSCs also have the potential to generate developmentally competent eggs. However, because such functional testing of human OSCs in vivo is not possible, strategies to mature human eggs derived from OSCs entirely ex vivo will be needed. In this regard, Telfer and McLaughlin have reported a multistep culture system in which microthin human ovarian cortical strips are maintained under defined serum-free conditions to initiate primordial follicle growth activation (28, 29) . Once the preantral stage of development is reached, the follicles are dissected out and subsequently cultured individually until the enclosed oocytes can be aspirated for in vitro maturation to metaphase-II eggs. Should this methodology prove successful (30) , it may provide an opportunity to test the developmental potential of human OSCs to form functional eggs ( Fig. 1) , given that human OSCs have already been shown to generate primordial oocytes contained in follicles in adult human ovarian cortical strips (8, 12) . In addition to the ability to test the competency of oocytes derived from OSCs recombined with somatic cells and other support necessary for ensuring ex vivo development, the innate oocyte-forming capability of these cells is valuable for other reasons. During serial passage of pure OSC cultures (i.e., with no somatic or feeder cells) under defined conditions, a small subset of OSCs spontaneously initiate a differentiation process that results in the formation of what appear to oocytes (8, 12) . Although these oocytes are not functionally competent (having never been associated with nor instructed by granulosa cells), they can be used as a powerful bioassay to rapidly decipher the factors and signaling pathways that guide oogenesis (Fig. 1 ). This can be achieved by assessing the rate of formation of in vitro-derived oocytes from a fixed number of OSCs exposed in different wells to various agents (12, 14) . In addition to the scientific value of such knowledge, large-scale screening of cultured OSCs may facilitate identification and development of therapeutics to sustain or restore the ovarian reserve in women of advancing maternal age or after exposure to noxious insults such as chemotherapy. Although more work is clearly needed to test these ideas, at this stage we believe it is appropriate to, at minimum, end further debate over whether mammalian OSCs exist, and instead constructively focus on what additional experiments are needed to more clearly define the regulation and function of these newly discovered cells in female reproductive biology. Follicular development and oocyte maturation are essential processes for successful ovulation to produce competent eggs ready for fertilization. Historically, it has been unclear whether the oocyte or the surrounding granulosa cells orchestrate the rate of follicular growth. Elegant work from the last decade shed considerable light on this process. Studies utilizing chimeric reaggregated mouse ovaries consisting of half-grown 12-day-old oocytes and newborn granulosa cells revealed that these stage-mismatched ovaries could undergo follicular development from primary to antral follicle stage at twice the normal rate. However, recent studies also uncovered the importance of ovarian somatic cells in the regulation of folliculogenesis and oogenesis. Here, we discuss bidirectionalcommunication between oocytes and their companion somatic cells during follicular development and oocyte maturation, which ensures normal female fertility.
Bidirectional Communication Between the Oocyte and Surrounding

inTRODuCTiOn
In mammals, primordial germ cells (PGCs) divide and migrate to the germinal ridge to become oogonia, which begin meiotic division during prenatal life. Around the time of birth, a cohort of oocytes recruits a single layer of flattened pre-granulosa cells to form the primordial follicles (1). Folliculogenesis starts with activation of a primordial follicle, which progresses through primary, secondary, and antral follicle stages, and finishes by either generating a fertilizable oocyte or follicular atresia. It was not clear previously that the rate of ovarian follicular development was dominantly controlled by either oocytes or neighboring somatic cells until a key study was done in the last decade (2) . In this study, mid-sized oocytes from the secondary follicles of 12-day-old mice were isolated and combined with somatic cells from primordial follicles of newborns to produce reaggregated ovaries. As a result, the 12-day-old oocyte prompted the proliferation and differentiation of both cumulus and mural granulosa cells and doubled the rate of follicular development to generate competent oocytes ready for fertilization. Thus, this study demonstrated that a developmental program intrinsic to the oocyte is crucial for orchestrating the rate of follicular growth and fundamentally changed our understanding of the regulation of ovarian follicular development.
OOCyTe-SeCReTeD FACTORS in The TRAnSFORMing gROWTh FACTOR β (TgF-β) PAThWAy
In follicular development, the mammalian oocyte modulates granulosa (directly) and thecal cell (indirectly) proliferation and differentiation rates through multiple oocyte-secreted factors (3). Among those factors, growth differentiation factor 9 (GDF9) and bone morphogenetic protein 15 (BMP15) are well known as two of the most important paracrine factors to prompt primary follicle growth as well as subsequent participation in the various stages of folliculogenesis (4). GDF9 and BMP15 are close paralogs in the TGF-β superfamily and signal via the downstream P-SMAD2/3 or P-SMAD1/5/8 pathway, respectively, to stimulate proliferation and differentiation of granulosa cells. Animal models deficient in these two ligands have been used to study their in vivo functions at the early stages of follicular development between poly-and mono-ovulatory mammals (Table 1 ). In mice, Gdf9 null females are sterile due to an arrest of follicular growth at the primary follicle stage (5) . Bmp15 null mice exhibit later defects in ovulation and fertilization rates, which lead to reduced litter size (6) . In sheep, homozygous BMP15 mutants exhibit a block in folliculogenesis at the primary follicle stage, resulting in sterility similar to that of Gdf9 null mice (7) . A homozygous point mutation in sheep GDF9 also results in abnormalities at early stages of follicular development (8) . In humans, although there is no direct evidence to prove that BMP15 and GDF9 are major causes of ovarian insufficiency, multiple studies have found that these two genes are associated with premature ovarian failure (9-11) or spontaneous dizygotic twinning (12) . Therefore, these genetic data indicate that both GDF9 and BMP15 play important roles in the transition between primary and secondary follicles as well as in ovulation. However, which of the two proteins is the dominant regulator might differ due to varying protein activities and expression patterns among species.
To further resolve the functions of these two growth factors and their potential synergistic functions in later follicle developmental stages, recombinant GDF9 or/and BMP15 were used to treat granulosa cells in vitro. In a recent study, our group purified human (h) and mouse (m) recombinant GDF9 and BMP15 homodimers and heterodimers to define their activities in pre-ovulatory follicles (13) . We showed that mGDF9 homodimer was a potent trigger of the TGF-β signaling cascade and upregulated downstream cumulus expansionrelated gene expression to induce the proliferation and differentiation of granulosa cells, while mBMP15 homodimer was inactive. By contrast, hGDF9 homodimer was inactive, and hBMP15 homodimer had a relatively low activity compared to mGDF9. In our studies, m/ hGDF9:BMP15 heterodimers were the most biopotent ligands in the regulation of ovarian function.
negATiVe OOCyTe RegulATORS in The PhOSPhATiDylinOSiTOl 3 kinASe (Pi3k) PAThWAy Granulosa cell-derived kit ligand is a positive regulator, stimulating oocyte growth and somatic cell proliferation. After binding with kit ligand, the kit receptor mediates PI3K signaling cascades in the oocyte via many downstream regulators. Among these regulators, several key components of the PI3K pathway function as suppressors of follicular activation at the early stages of follicular development. Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a major negative regulator. Mice lacking Pten in the oocyte exhibit premature ovarian failure due to depletion of primordial follicles in early adulthood (14) . FOXO3A, a forkhead transcription factor, is another important downstream negative effector of the PI3K pathway. Phosphorylation of FOXO3A leads to its nuclear export and the regulation of genes involved in primordial follicle activation. Foxo3a knockout female mice are phenotypically similar to Pten oocyte-specific knockout mice (15) . These animal models could help unravel the etiology of infertility and premature ovarian failure in women and enable clinical intervention.
MeiOTiC ARReST AnD ReSuMPTiOn RegulATiOn ViA gAP JunCTiOnS
Synchrony between oocyte meiosis and follicular ovulation is required for female fertility. Granulosa cells maintain oocyte meiotic arrest via the natriuretic peptide C/natriuretic peptide receptor 2 (NPPC/NPR2) system (16) . Mural granulosa cells produce the NPPC ligand, which binds to the receptor NPR2, a guanylyl cyclase in cumulus cells, resulting in cyclic guanosine monophosphate (cGMP) generation. cGMP diffuses from cumulus cells to the oocyte via gap junctions and then inhibits PDE3A, an oocyte-specific phosphodiesterase, to maintain elevated cyclic adenosine monophosphate (cAMP) in the oocyte (17, 18) . High levels of cAMP require the orphan Gs-linked receptor GPR3 to prevent precocious gonadotropin-independent resumption of meiosis (19) . After the LH surge, PDE3A becomes activated, decreasing the oocyte cAMP concentration and thus triggering the downstream pathways to resume meiosis during ovulation (20) . As a dominant factor, the oocyte controls meiotic arrest not only by maintaining high cAMP levels but also by secreting certain paracrine growth factors (including GDF9 and BMP15) to elevate NPR2 expression in cumulus cells (16) . Furthermore, a novel oocyte protein, named meiosis arrest female 1 (MARF1), has been identified as an oocyte maturation regulator by recent ENU mutagenesis screening (21) . Mutations of Marf1 leads to infertility characterized by the failure of meiotic resumption, upregulation of protein phosphatase 2 catalytic subunit beta (PPP2CB), and an increase in DNA damage in the ovulated oocytes.
COnCluSiOnS AnD iMPliCATiOnS
In summary, genetic data generated over the past few decades
An Introduction to Human Embryo Development
Renee A. Reijo-Pera Human embryo development begins with an oocyte-to-embryo transition, a process that includes the fusion of the egg and sperm, migration of the germ cell pronuclei into the uterus, pronuclear membrane breakdown, and a series of cleavage divisions. This culminates in the activation of the unique human embryonic genome, compaction of the blastomeres to form a morula, and subsequent differentiation of the first cell lineages-the trophectoderm and inner cell mass (1). In humans, there is a minor wave of transcriptional activation early in development and a major wave that constitutes embryonic genome activation (EGA) on day three of embryogenesis (2) . Human embryo development is remarkable in that the oocyte provides the majority of the required resources to direct the complex developmental pathways during the first three days of development, in the absence of large-scale transcriptional activity (2) . Consider further that native have identified three major pathways that mediate the communication between oocyte and somatic cells ( Fig. 1 ): (i) oocyte-secreted GDF9, BMP15, and GDF9:BMP15 heterodimer which stimulate TGFβ signaling in granulosa cells; (ii) granulosa cell-derived kit ligand that binds to kit receptor on the oocyte and triggers downstream PI3K signaling; and (iii) secondary messengers, which are transferred via oocyte-cumulus cell gap junctions. Although the oocyte is the dominant factor orchestrating the onset of folliculogenesis and regulating somatic cell proliferation and differentiation during follicular development, other regulators in the oocyte-somatic cell regulatory loop are also indispensable for normal female fertility (22) . Thus, progression through successive stages of follicular development and oocyte maturation requires bidirectional communication between the oocyte and surrounding somatic cells.
Species Gene Mutant Phenotype
Mouse
Gdf9
Heterozygous Normal fertility (5) Homozygous Sterility due to block at primary follicle stage (5)
Bmp15
Heterozygous Normal fertility (6) Homozygous Subfertility due to defects in cumulus expansion (6)
Sheep
GDF9
Heterozygous Increased ovulation rate resulting in increased offspring (e.g., dizygotic twins) (8) Homozygous Sterility due to block at primary follicle stage (8)
BMP15
Heterozygous Increased ovulation rate resulting in increased offspring (e.g., dizygotic twins) (7)
Homozygous Sterility due to block at primary follicle stage (7) Human GDF9 Heterozygous Associated with premature ovarian failure (9) or spontaneous dizygotic twinning (12) Homozygous Not reported
Heterozygous Associated with premature ovarian failure (10, 11)
Homozygous Not reported Table 1 . GDF9 and BMP15 mutants in mouse, sheep, and human.
human reprogramming from gametic pronuclear programs to embryonic programs involves the epigenetic remodeling of one of the most challenging sets of chromosomes to reprogram, those inherited from analysis of single embryos and embryonic blastomeres (6) . Results indicated that euploid embryos could not be accurately distinguished from those with aneuploidies when only cell cycle parameters were analyzed. By adding additional confocal microscopy analysis (which included reconstruction of all blastomere karyotypes to the four-cell stage), however, we concluded that the complexity in human embryonic aneuploidy is not simply due to errors on the meiotic/mitotic spindle. Rather, results suggested that generation of aneuploidy may also occur during interphase and can be explained by the containment of a subset of missing chromosomes within cellular fragments, which bud off from embryonic blastomeres and may persist or become reabsorbed. We also noted that chromosome-containing fragments may arise from micronuclei, or embryonic structures distinct from primary nuclei, with encapsulated chromosome(s) detected only in the blastomeres of cleavage-stage human embryos ( Fig. 1 ). These findings suggest that individual human blastomere behavior is diagnostic of chromosomal status and provides the first example of the use of non-invasive imaging and automated fragmentation tracking to distinguish euploid and aneuploid cells. These studies predict the sperm (1). These chromosomes are highly condensed, highly methylated, and organized around a protamine scaffold rather than a histone scaffold. Yet, it is clear from several studies that native reprogramming in the human oocyte-to-embryo transition succeeds in over 75 percent of embryonic blastomeres (3); moreover, advances in somatic cell nuclear transfer (SCNT) procedures have revealed the robust ability of human oocytes to reprogram somatic DNA (4).
uSe OF nOninVASiVe TiMe-lAPSe iMAging TO PReDiCT DeVelOPMenTAl FATe
Over the last decade, key studies in human embryo development have used time-lapse imaging of embryogenesis to elucidate the role of various cell cycle parameters and factors that may predict success or failure in the embryo reaching the blastocyst stage and beyond. In 2010, Wong et al. reported the use of time-lapse microscopy and gene expression profiling at the single embryo and blastomere level to document the growth of human embryos from zygote to blastocyst (3). Key developmental features were extracted and algorithms generated to predict success and failure in development leading up to the blastocyst stage; morphological assessment was augmented by a comparison of gene expression in embryos that succeeded or failed to develop. These studies indicated that the characteristics of the first cytokinesis and the first two cleavage divisions could be used as markers for a positive outcome. Successful development was shown for the first time to be highly regulated, following strict timing in pre-implantation development even prior to EGA. In normal development, degradation of maternal mRNA was shown to precede cell autonomous EGA. In contrast, arrested embryos most often displayed aberrant cytokinesis during the first cleavage divisions prior to EGA, accompanied by equally aberrant gene expression in the embryo or individual blastomeres. Since the studies by Wong and colleagues suggested that human embryo fate could be predicted accurately prior to EGA, it was proposed that success and failure is often inherited. Embryos that begin life with defective maternal programs, or inherit defective paternal components, are likely to display aberrant cytokinesis, embryo fragmentation, and arrest of individual blastomeres or the entire embryo. The methods and algorithms described by Wong et al. provided a platform for improved and earlier diagnosis of embryo potential to hopefully allow for the transfer of fewer embryos earlier in development during assisted reproduction procedures. Subsequent reports have documented that the parameters identified are able to provide predictive power beyond the blastocyst stage, to implantation, and that other parameters may be added for ease of use or to adapt the technology to clinics that differ in terms of cell culture media, patient base, or other characteristics (5).
exTenSiOn OF STuDieS TO unDeRSTAnDing geneSiS OF AneuPlOiDy
Based on the results of Wong et al., we hypothesized that measurement and analysis of specific parameters in preimplantation human embryos could provide insight into fundamental characteristics of the embryo, including ploidy. We first sought to correlate normal and abnormal development by correlating continual imaging with genetic Human embryos with meiotic errors (monosomies and trisomies) and those that appear to be triploid typically exhibit fragmentation at the one-cell stage, while fragmentation is most often detected at the two-cell stage in embryos with mitotic errors. We also demonstrated that missing chromosome(s) are contained within fragments termed "embryonic micronuclei" and for those embryos with mitotic errors, propose that the embryo likely divided before these chromosomes properly aligned on the mitotic spindle. The correlation between the timing of fragmentation and the type of embryonic aneuploidy suggests that the embryo can sense chromosomal abnormalities and undergoes fragmentation as a survival mechanism. As development proceeds, these fragments either remain or are reabsorbed by the blastomere from which they originated, or a neighboring blastomere, to generate the complex human aneuploidies observed. Image from (6) .
that a combination of time-lapse parameter analysis, along with assessment of blastomere fragmentation dynamics (Fig. 2) , may reduce the inadvertent transfer of aneuploid embryos, with implications for decreasing miscarriage risk and improving in vitro fertilization success. Based on this work, we have offered a model of aneuploidy development during human embryogenesis that is currently being further examined (Fig. 3 ).
SuMMARy
Numerous basic and clinical laboratories are now investigating the use of noninvasive time-lapse imaging to provide reliable information regarding the development of human embryos to the blastocyst stage, implantation, and beyond. It is hoped that advances will enable the separation of those embryos that are most likely to develop successfully from those that likely would result in miscarriage or still-birth due to severe birth defects.
inTRODuCTiOn
We have investigated the effects of two environmental toxicants (vinclozolin and methoxychlor) following exposure of rats during fetal gonadal sex determination, and the impact on gonadal development and function (1, 2) . A serendipitous observation was made when F1 generation animals were mistakenly bred to generate the F2 generation offspring: the vast majority of the testes in the F2 generation carried a spermatogenic cell defect that induced apoptosis. This prompted a multiple year study that demonstrated the phenomenon of environmentally induced epigenetic transgenerational inheritance of disease for the first time (3). This study showed an increase in apoptosis in testis spermatogenic cells in the F1, F2, F3, and F4 generations, as well as in outcrossed offspring, through non-Mendelian genetic inheritance, affecting 90% of the male population. The causative epigenetic effects were traced to specific DNA methylation sites. The impact of this study on our understanding of the molecular control of inheritance, disease etiology, and environmental toxicology is significant. Over the past ten years a series of studies have further investigated this phenomenon, including environmental factor specificity, germline epigenetics, and disease etiology (4, 5) .
ePigeneTiC TRAnSgeneRATiOnAl inheRiTAnCe
The definition of epigenetic transgenerational inheritance is "germline mediated inheritance of epigenetic information between generations that leads to phenotypic variation in the absence of direct environmental influences" (6) . This is in contrast to epigenetic inheritance that involves direct environmental germline or somatic cell exposure, and epigenetic responses during early development that influence phenotypes in later life. An example is the Agouti mouse model, which responds to an environmental signal in utero through a change in an epiallele, thus shifting the coat color of the offspring (5, 7) . Environmental epigenetic inheritance responses may be corrected in subsequent generations during epigenetic reprogramming of the germline or early embryo, such that the phenotype is lost (8, 9) .
In order for environmentally induced epigenetic transgenerational inheritance to occur, the external insult must act on a gestating female during fetal gonadal sex determination, influencing the epigenetic programming through altered DNA methylation patterns in the germline (Fig. 1 ). The epigenetic information is then carried through the epigenome of the germline, into the embryonic stem cell, and thus to all somatic cells of the offspring. Susceptible tissues in offspring will potentially develop disease and the defect will continue to be transgenerationally inherited (Figs. 1 and 2) (3-5). Several studies, described below, support this hypothesis of the molecular etiology of epigenetic transgenerational inheritance.
geRMline ePiMuTATiOnS AnD exPOSuRe (TOxiCAnT) SPeCiFiCiTy
The environmental compound (toxicant) administered in the initial study was vinclozolin, one of the most widely used agricultural fungicides (3). The outcross information from this work indicated that the transgenerational phenotype was transmitted through the male sperm (3). A genome-wide promoter analysis identified approximately 50 differentially methylated regions (DMRs) in the sperm of the F3 generation from vinclozolin-treated animals when compared with sperm from matched control (vehicle exposed) F3 rats (10) . The DMRs carry epimutations that can transmit this epigenetic information transgenerationally (4) .
A critical question was whether this phenomenon was unique to vinclozolin. A series of studies investigated the actions of dioxin (11), a pesticide and an insect repellent (permethrin and DEET) (12) , plastics (BPH and phthalates) (13) , and hydrocarbons (JP8 jet fuel) (14) . All were found to promote the transgenerational inheritance of sperm epimutations and of disease (15) . Interestingly, each toxicant promoted a unique set of epimutations with negligible overlap (Fig.  3) (15) . These studies did not measure true environmental risk, but provide a good foundation for future analysis to determine the environmental hazards of exposure. Others have now shown transgenerational inheritance of disease as a result of exposure to various environmental factors including nutrition (16) , stress (17) , and other toxicants (18) . Combined observations suggest that epigenetic biomarkers for ancestral toxicant exposure and adult onset disease may exist.
TRAnSgeneRATiOnAl inheRiTAnCe OF DiSeASe AnD PhenOTyPiC VARiATiOn
The first transgenerational abnormality observed was an increase in spermatogenic cell apoptosis (3, 19) . Other abnormal pathologies seen (Fig. 1 ) included prostate disease (11-15, 20, 21) , kidney disease (11) (12) (13) (14) 20) , mammary tumors (20) , immune system abnormalities (14, 20) , and behavioral effects such as anxiety (22) . Other laboratories have shown transgenerational effects on reproduction (23, 24) , stress response (25) , and obesity (14, 26) . Some transgenerational diseases were induced by a variety of different environmental exposures (15) , including polycystic ovaries and reduction of primordial ovarian follicle pool size, which were found in the majority of females from all exposure groups examined (27 Epigenetic transgenerational inheritance may also impact other areas of biology. One study found that the F3 generation of vinclozolintreated rats had significant altered mate preference behavior (28) . Since sexual selection is a major determinant in evolutionary biology, this work suggests that transgenerational epigenetics may play a critical role in evolution (4).
TRAnSgeneRATiOnAl SOMATiC TRAnSCRiPTOMeS AnD The eTiOlOgy OF RePRODuCTiVe DiSeASe
Transgenerational germline transmission of epimutations results in all somatic cells in offspring carrying an altered methylation pattern and transcriptome (4, 6) . Building upon earlier transgenerational transcriptome studies in fetal rat testis (29), we examined the transgenerational transcriptomes of 11 different tissues in male and female vinclozolin-treated versus control lineage rats (30) . All tissues had a transgenerational transcriptome that was unique to the specific tissue, with negligible overlap between tissues. It is intriguing that a relatively small number of epimutations can produce such a large number of specific transcriptome changes (30) . The identification of epigenetic control regions-areas of 2-5 megabases with an overrepresentation of regulated genes close to DMRs and long noncoding RNA regions-may provide a clue (Fig. 4 ) (30), suggesting unique molecular regulatory mechanisms that will require further investigation.
To further elucidate the role of epimutations in adult onset disease, the molecular etiology of ovarian diseases were studied (27) . Follicular somatic granulosa cells were found to have an altered epigenome and transcriptome that suggested specific signaling pathways were affected. Similarly, somatic Sertoli cells in the testis were found in a separate study to have transgenerational alterations in their epigenomes and transcriptomes, affecting genes previously shown to be involved in male infertility (31) .
iMPACT AnD FuTuRe STuDieS Our original publication (3) described the phenomenon of environmentally induced epigenetic transgenerational inheritance of a disease. Subsequent publications confirmed and clarified the molecular and physiological parameters involved. The research shows the existence of a non-genetic (i.e., epigenetic) form of transgenerational inheritance that impacts the etiology of certain diseases, as well as a potential molecular mechanism describing how environmental factors could directly influence gene expression and therefore disease (4, 5) . Further studies clearly are needed to clarify the role of epigenetics and transgenerational inheritance in disease etiology, evolutionary biology, and other areas of cell and developmental biology. The specific next steps needed include investigation into why specific sites are more susceptible to becoming transgenerationally programmed and the mechanism by which this occurs, as well as the translation of this work from animals to humans. These and other studies will undoubtedly have significant impact on our understanding of normal biology and disease etiology.
Aberrant Endocannabinoid Signaling is a Risk Factor for Ectopic Pregnancy
Xiaofei Sun and Sudhansu K. Dey * According to the U.S. Centers for Disease Control and Prevention, ectopic pregnancy is the leading cause of pregnancy-related death during the first trimester (1). In the United States, around 100,000 women encounter ectopic pregnancies each year, and 6% of maternal deaths are attributable to ectopic pregnancies (2) . Although ectopic pregnancy adversely affects female reproductive health, its etiology remains elusive. It was discovered that cannabinoid receptor 1 (CB1)-deficient mice demonstrated spontaneous oviductal retention of embryos at the blastocyst stage (3), making these mice a good model to study certain aspects of ectopic pregnancy.
In normal pregnancy, eggs are fertilized and undergo further development to embryos within the oviduct in mice or the Fallopian tubes in humans. Mouse embryos develop within the oviduct for about 72 hours, and then transit through the utero-tubal junction to enter the uterus. The normal passage of embryos through the oviduct into the uterus requires coordinated oscillation of the cilia on the oviductal epithelium, as well as muscle contractions. Upon arrival in the uterine cavity, embryos develop to the blastocyst stage and become activated (implantation competent); they can then implant in the uterus if the uterine environment is conducive to implantation.
In ectopic pregnancies, embryos implant outside of the uterine cavity; in humans, 98% of ectopic pregnancies occur in the Fallopian tubes and are known as tubal pregnancies. Two prerequisites of tubal pregnancy are Fallopian tube retention of embryos and an abnormal tubal environment that is conducive to implantation. A diagnosis of tubal pregnancy often requires multiple visits to the doctor and there is the danger that the implanted embryo will rupture within the Fallopian tube potentially resulting in maternal death (4) . Although some of the risk factors for tubal pregnancy are known, such as tubal damage from surgery or infection, cigarette smoking, and in vitro fertilization procedures, the precise mechanism by which embryo implantation in the Fallopian tube occurs is not completely understood (5) .
Tubal pregnancy occurs rarely in other mammals and the lack of animal models has made it difficult to study the underlying mechanisms. Extra-uterine implantation usually occurs in the abdominal cavity in animals, and just a few cases of tubal pregnancy in primates have been reported (6, 7) . There are no known cases of full ectopic pregnancy in mice, possibly because the walls of mouse oviducts are thin compared with human Fallopian tubes. It is also possible that implantation-specific genes expressed in the uterus are not displayed in the mouse oviduct. Nonetheless, mouse models have been used to study certain aspects of oviductal embryo retention (8) . One such rodent model, CB1-deficient mice, was the first to demonstrate spontaneous oviductal retention of embryos, providing a useful tool to study certain mechanisms of ectopic pregnancy (9) .
CB1 is a G protein-coupled cannabinoid receptor that is targeted by cannabis and endocannabinoids, a group of endogenous cannabis-like compounds that act as lipid mediators. The two most extensively studied endocannabinoids are anandamide (AEA) and 2-arachidonoylglycerol (2-AG) (9) . Levels of endocannabinoids in vivo are tightly regulated by enzymes controlling their synthesis and degradation. The magnitude and duration of AEA signaling is regulated by a membrane-bound fatty acid amide hydrolase (FAAH), which is also capable of degrading 2-AG to arachidonic acid and glycerol (9) . In mice, endocannabinoids and CB1 are present in the oviduct. FAAH protein levels in the isthmus are lower than those in the ampullary region (10, 11) , suggesting a gradient of AEA in the oviduct.
In mice, the movement of embryos within the oviducts is aided mainly by the beating of cilia located on the oviductal epithelium (12, 13) ; meanwhile, the transport of embryos from the oviduct to the uterus is facilitated by a wave of oviductal muscle movement (14) . Muscular movement is controlled by the peripheral sympathetic nervous system (15) . Stimulation of the β2 adrenergic receptor (β2-AR) causes sphincter muscle relaxation, whereas stimulation of the α1-AR produces muscle contraction. It is believed that reciprocal stimulation of these two receptors causes a wave of contraction and relaxation, which is conducive to the passage of embryos from the oviduct into the uterine lumen (14, 15) .
Our group has shown that oviductal retention of embryos occurred in CB1-deficient mice (3). Reciprocal embryo transfer experiments further confirmed that maternal CB1 is critical for appropriate oviductal transport of embryos, since only CB1-deficient recipients displayed oviductal retention irrespective of embryo genotype ( Fig. 1) (3) . Our laboratory also found that higher cannabinoid signaling affects oviductal embryo transport. Wild-type (WT) mice exposed to Δ 9 -tetrahydrocannabinol (THC, the active psychoactive component of marijuana) or methanandamide (a stable AEA analog) showed similar oviductal embryo retention, which was rescued by treatment with a CB1 antagonist (11) . Studies using FAAHdeficient mice further confirmed that higher oviductal AEA levels disrupt normal oviductal embryo transport. Taken together, the results demonstrated that either higher or lower endocannabinoid signaling impairs normal wave movement through the oviduct, and consequently derailed normal oviductal transportation of embryos.
Our studies in mice stimulated research on ectopic pregnancy in women and many of the findings in humans were consistent with the results of the mouse studies. In women with ectopic pregnancies, the Fallopian tubes and endometria showed lower levels of CB1 compared with those in women with normal pregnancies (16) . AEA levels in ectopic Fallopian tubes were significantly higher than those in normal pregnancies (17) , and increased AEA levels were associated with low FAAH activity in ectopic Fallopian tubes. In addition, treatment with oleoylethanolamide, an endocannabinoid, significantly decreased cilia oscillation frequency displayed on the Fallopian tube epithelium (18) . These results suggest that disturbances in cannabinoid signaling during early pregnancy could result in ectopic pregnancy in humans. It would be interesting to explore whether polymorphisms in the gene encoding the CB1 receptor are associated with ectopic pregnancy in humans.
A national survey of marijuana use from 1991 to 2011 in students grades 9-12 showed a rise in usage of this Schedule I drug (19) . Since synthetic cannabinoids appeared in 2008, the popularity among high school seniors and persons under 25 years of age has increased sharply (20, 21) . Synthetic cannabinoids are found in illicit "fake marijuana" with street names such as "Spice" or "K2." Many synthetic cannabinoids have much higher affinities for cannabinoid receptors and are more potent compared to natural cannabis. This increase in marijuana and synthetic cannabinoid use is potentially troubling when combined with the aforementioned statistic that ectopic pregnancy accounts for about 6% of all pregnancy-related deaths in the United States (2). Therefore, our studies not only provide a useful animal model to study ectopic pregnancy, but also draw more public attention to the adverse effects of maternal usage of marijuana and synthetic cannabinoids. supported by a Lalor Foundation postdoctoral fellowship in reproductive biology.
The wide application of in vitro fertilization has caused a dramatic increase in multiple births, associated with adverse neonatal outcome, mainly as a result of the transfer of several embryos per cycle. Randomized controlled trials, observational studies, and meta-analyses were carried out to investigate pregnancy and live-birth rates after single (SET) or double embryo transfer (DET) as well as obstetrical outcomes. Results showed that the live-birth rate was significantly higher after DET than SET if only fresh cycles were compared. If one additional frozen/thawed SET was added to the SET group, live-birth rates did not differ substantially. Obstetrical outcomes were considerably improved with the SET strategy. We therefore conclude that SET is the more desirable option for a majority of patients.
inTRODuCTiOn
The rapid development of different in vitro fertilization (IVF) techniques has resulted in increasing pregnancy and live-birth rates per cycle. In parallel, a dramatic increase in multiple births has occurred. Numerous publications have demonstrated higher risks for an adverse outcome, including preterm birth (PTB, <37 weeks), low birth weight (LBW, <2,500 g), and perinatal mortality for children born after IVF, compared with children born after spontaneous conception, mainly due to the high rate of multiple births following IVF (1-3) . Also, for IVF singletons, increased rates of PTB and LBW were noted (3-5), likely caused by inherent characteristics of the infertile couple such as the mother's age and nulliparity. An increase in the frequency of neurological sequele has also been found, strongly associated with PTB and multiple births (6) . An increased rate of physical malformations has been reported for children born following IVF (7).
The most important factor affecting the rate of multiple births is the number of embryos transferred during IVF. Reducing the number of transferred embryos from three to two had little effect on live births, but decreased the rate of multiple births; the observed twin rate was, however, still high (8). Data from large registry studies-many performed in Sweden-on obstetrical outcomes after IVF showed an increased rate of severe medical problems in IVF children, generating an intensive debate in Sweden among obstetricians, paediatricians, doctors in reproductive medicine, and politicians. There was a call for transferring only one embryo during IVF, a strategy supported by some reports that single embryo transfer results in satisfactory pregnancy rates (9) .
The aim in the trial discussed here (10) was to investigate whether a similar live-birth rate could be achieved if two embryos were transferred one at a time-one fresh embryo, and if no live birth was detected, one additional frozen/thawed embryo-rather than the standard practice of transferring two embryos on a single occasion, and whether this would decrease the multiple birth rate.
MeThODS
were randomly assigned to two groups, SET and DET. The study was double blind, so neither the physician nor the patient knew whether one or two embryos had been transferred. The number of patients needed in each group (330) was based on the assumptions that the true livebirth rate in both groups would be 0.30 and the probability is 0.80 that the upper limit of the 95% confidence interval (CI) for the difference in live-birth rates between the groups did not exceed 0.10 (a=0.05).
MAin ReSulTS
The results showed that the live-birth rate was 128/330 (38.8%) in the SET group and 142/331 (42.9%) in the DET group (95% CI for the difference: 0.3-11.6). Thus equivalence between the two groups could not be demonstrated, but the live birth rate did not differ substantially between SET and DET. Moreover, the multiple birth rate was dramatically reduced in the SET compared to the DET group: 0.8% (1) vs 33.3% (47) (p<0.001). Most important, the neonatal outcome was considerably better for children born to the SET group, with significantly lower rates of PTB (11.6% vs. 29.1%, p=0.002) and LBW (7.8% vs. 27.5%, p<0.0001). The SET group showed less severe neonatal complications demanding neonatal care in hospital (17.8% vs. 33.9%, p=0.003) and also a lower rate of complex morbidity (7.8% vs. 24.3%, p=0.0001) (11) . A financial analysis indicated that the SET strategy was cost-effective; the incremental cost-effectiveness-ratio (ICER) was €73,307 ($99,089) per additional delivery in the DET alternative.
FuRTheR DeVelOPMenT
Several randomized trials and meta-analyses (12, 13) have compared the delivery rates in SET and DET groups. The studies have shown significantly higher pregnancy and delivery rates after DET compared to SET when only fresh cycles were compared. Performing an additional frozen/thawed SET in the SET group resulted in a delivery rate comparable with that in the DET group (10). The Scandinavian countries, particularly Sweden, have played a pioneering role in reducing multiple births by introducing SET on a large scale. In Sweden, this strategy has resulted in no change in delivery rates for fresh or frozen/thawed cycles, while the rate of multiple births has decreased dramatically, from 25% to around 5%. The overall SET rate is 70%-80% (Fig. 1) . Delivery-and multiple birth rates after SET and DET according to age are illustrated in Figure 2 . A gradual increase in SET rates has been seen worldwide, including
PeRCenT yeAR
Scandinavia and other northern European countries such as Belgium and the Netherlands, as well as in Australia, New Zealand, and Japan. The United States has lagged behind in applying SET (14) . Although the rate of multiple births has decreased in recent years, it is still high in many countries. The latest report indicates that the multiple birth rate in Europe is 22% (2008) and in the USA is 31% (2009) (15, 16) .
RATiOnAle FOR nOT APPlying SeT
Fears among both patients and clinicians that SET will lower pregnancy and live-birth rates is probably the most common reason given for not applying SET more broadly. A focus on short-term higher success rates (pregnancy rate per cycle), rather than optimal outcomes, i.e., the birth and health of a singleton, has slowed progress in this area.
Despite the overwhelming data indicating increased risks associated with multiple births, there is still an ongoing debate whether, in particular, twins are a desired outcome for IVF. It has been claimed that the risks associated with IVF twins are dramatically exaggerated and that twins should be encouraged (17) . There are also financial variables for patients involved to be considered, and large differences exist in reimbursement systems for IVF in different countries, which influences utilization of SET. In countries where IVF is completely or partially covered by public funding, SET has been accepted more readily. If patients are self-funded, they might choose more embryos to be transferred in order to maximize the chance of becoming pregnant.
Other factors impacting SET acceptance include a lack of knowledge concerning the risks of multiple births, failure to consider cumulative live birth rates that include frozen/thawed cycles, differences in legislation between countries, and impediments stemming from cultural beliefs.
COnCluDing ReMARkS
The most important risk associated with IVF is the higher rate of multiple births, resulting in increased child morbidity and mortality. In addition to problems in the neonatal period, preterm birth and low birth weight may have long-term consequences for future health. According to the Barker hypothesis (18), these adverse outcomes may lead to increased risk of type 2 diabetes and cardiovascular diseases in adulthood.
The association between IVF and a poorer obstetric outcome for singletons has also been widely documented, but is quantitatively a much smaller problem. Maternal characteristics seem to be the largest contributors to these adverse outcomes (19) , while the contribution of IVF-related factors is less clear.
Recent data from Sweden indicates that it is possible to have two consecutive singleton births in the same or similar number of fresh IVF cycles using the SET strategy as with the DET strategy by simply adding a small number of frozen/ thawed cycles, while concomitantly avoiding the risk of multiple births (20) .
Current knowledge strongly supports SET as an IVF strategy that is safe and effective for mothers and children.
Oocyte Vitrification: A Major Milestone in Assisted Reproduction
Ana Cobo
The cryopreservation of female gametes has been pursued since the onset of assisted reproductive technology (ART). After a lengthy period of failures and sporadic successes, the introduction of refined vitrification methods has meant a huge step forward in infertility practice as it allows efficient egg cryostorage. Today, the clinical use of oocytes that have been stored in cryogenic tanks is an accepted practice. The very broad scope of this technology encompasses various new areas such as fertility preservation for social or oncological reasons, the possibility of creating egg banks for ovum donation, and the opportunity to avoid ovarian hyperstimulation syndrome, or to accumulate oocytes in low-responder patients. Even segmented infertility treatments can be offered by stimulating ovaries, vitrifying embryos, and then transferring them during a natural cycle. All of these options were not available just a few years ago, but are now being routinely applied in increasingly more infertility centers worldwide.
inTRODuCTiOn
The development of efficient cryopreservation techniques for female gametes has been a real challenge as both freezing and thawing expose oocytes to severe stress that can result in cell death. The introduction of improved vitrification methods has meant increasingly successful outcomes, where the most commonly applied methodology since the onset of ART-slow freezing-has led to limited success (1, 2) . Among the reasons for failure resulting from slow freezing, chilling injury and ice formation are recognized as being the most deleterious (3). Chilling injury is avoided with vitrification because cooling occurs extremely rapidly and ice formation is circumvented very efficiently by using high concentrations of cryoprotectants (CPAs). Application of vitrification has been limited since it was first employed in embryology in the early 1980s (4) because the concentration of CPAs required for the earliest vitrification protocols can have dramatic toxic effects. Significant changes made to these protocols have reduced the concentration of CPAs to circumvent deleterious consequences to cells (5) . The efficiency of modified protocols has been successfully tested clinically, which is an essential requisite for fertility preservation, ovum donations, or other clinical applications, and also to overcome certain clinical obstacles that ART posed, such as the absence of a partner's semen sample on inTRODuCTiOn Given a prevalence of one in six couples, infertility is one of the largest contemporary public health issues in Western countries. In vitro fertilization (IVF) is now widely available and is the most effective treatment for infertile couples. While clinical outcomes have improved since IVF was first introduced, the efficiency of the process remains low. In the most recent U.S. Centers for Disease Control and Prevention summary of IVF outcomes in the United States, fewer than 17% of embryos deemed of sufficient quality to merit transfer actually implanted and progressed to delivery. This fact reflects that morphologic and temporal markers of in vitro embryonic development have only modest predictive value when trying to assess the true reproductive potential of any single embryo. As a result of this uncertainly, patients and IVF providers elect to transfer multiple embryos in the hope that one with true reproductive potential will be included. While improving delivery rates, unacceptable rates of multiple gestations with significantly increased maternal and neonatal morbidity ensue.
ACCuRATe ASSeSSMenT OF eMBRyOniC RePRODuCTiVe POTenTiAl
Assessing embryonic competence brings special challenges not encountered elsewhere in clinical science. The reality is that embryos deemed to lack reproductive potential are discarded as biologic waste. Thus a misdiagnosis leads embryologists to throw out an embryo which might have been capable of becoming a baby. Some couples only rarely produce a competent embryo or may have limited access to care and thus such a misdiagnosis may lead them to discard their only meaningful opportunity for delivery. There is no other area of medicine where a single abnormal laboratory result causes clinicians or scientists to discontinue care with such irrefutable finality.
VAliDATing ASSAyS FOR eMBRyOniC AneuPlOiDy SCReening
Screening embryos for the correct number of chromosomes (euploidy) represents a well-founded concept given the direct correlation between increasing maternal age, decreased fecundity, and oocyte aneuploidy (1). Developing and validating a single cell embryonic aneuploidy assay is more complex than for other cell types, in part because access to biologic material for validation is difficult and limiting. There are no cell lines available of embryonic cells at this stage of development, but discarded embryos can be used for validation. Given the critical impact that screening has on management of individual embryos, the challenges of mosaicism, the fact that the assay may be required to work with only a single cell, and the complexity in demonstrating clinical benefit, validation of embryonic aneuploidy screening is a complex process requiring multiple studies at the basic laboratory and translational/clinical level. The study reviewed herein describes the first step in the complex process of validating a tool-single nucleotide polymorphism (SNP) arrays-for embryonic aneuploidy screening, namely standardizing the assay.
Accurate Single Cell 24 Chromosome Aneuploidy Screening
TARgeT DnA AMPliFiCATiOn SNP array technology provides an opportunity to simultaneously investigate the copy number of all 24 chromosomes. Unlike fluorescence in situ hybridization (FISH)-based testing, arrays require the incorporation of DNA amplification for which a variety of methodologies could be employed. Methods for whole genome amplification (WGA) were compared for performance on SNP arrays (2) . Results demonstrated superior performance of a PCR-based strategy when evaluating copy number accuracy (most relevant to aneuploidy screening).
A FOunDATiOnAl STuDy OF SnP ARRAy SCReening
This study was conducted in three phases (3). Single cells from a variety of cell lines with known chromosomal abnormalities were evaluated and data analysis settings were established to give the highest level of consistency. This calibration was necessary to define the methodology. Next, the same cell lines were used to prepare and blind single cell samples for analysis. Blinded analysis provided a rigorous test of the accuracy of the method on positive controls. Finally, multiple single cells from human embryos available for research were evaluated to demonstrate consistency of diagnoses in the relevant tissue type.
Analyses of Cell Lines
The SNP array approach analyses the relative intensity of binding for a large number of SNPs spread across the genome. Average intensities are considered to have a copy number of two. Those with lower intensity are assigned copy numbers of one (monosomy) and those with higher intensities are assigned copy numbers of three (trisomy). Given that embryonic aneuploidy typically involves the gain or loss of an entire chromosome, the results on a single chromosome should the day of ovum collection.
A comparison of embryo development using vitrified and fresh oocytes was performed (6) to provide valuable information about the further potential of vitrified oocytes, and to serve as a foundation for additional studies.
OOCyTe ViTRiFiCATiOn AnD eMBRyO QuAliTy
A prospective cohort study was used to perform a first of its kind analysis of the quality of embryos emerging from simultaneously generated vitrified and fresh donor oocytes (6) . All of the metaphase II oocytes assigned to a single recipient were randomly allocated one of two groups: vitrified (oocytes were vitrified and then warmed for one hour before implantation) or fresh (maintained in culture at 37°C). Intracytoplasmic sperm injection (ICSI) using the husband's semen sample was performed simultaneously on both vitrified and fresh oocytes. A high overall survival rate was achieved (97%; N=224 of 231 oocytes). No significant differences in fertilization rates for day one (76.3% vs. 82.2%), day two (94.2% vs. 97.8%), or day three (77.6% vs. 84.6%) embryo cleavage or blastocyst formation rates (48.7% vs. 47.5%) were detected for the vitrified and fresh oocytes, respectively. The ratios of good quality embryos on day three (80.8% vs. 80.5%) and in the blastocyst stage (81.1% vs. 70.0%) were similar in both groups. Additionally, promising clinical outcomes were obtained following the transfer of embryos developed from vitrified oocytes (40.8% for the implantation rate and 47.8% for the ongoing pregnancy rate). These outcomes are in contrast to those previously reported by other authors using a slow freezing methodology (1). The widespread introduction of oocyte vitrification into clinical practice has been greatly strengthened by these findings, which have demonstrated that both embryo developmental capability and implantation potential are essentially unaltered by oocyte vitrification.
COnTRiBuTiOn OF OOCyTe ViTRiFiCATiOn TO CuRRenT CliniCAl PRACTiCe
Our findings were further replicated by other authors with both donor and own oocytes [see (7) for review]. In a follow up controlled, randomized clinical trial we used a refined methodology to compare clinical outcomes utilizing both cryopreserved and fresh oocytes in an ovum donation program (8) . In this study, vitrified oocytes could not be shown to be inferior to fresh oocytes in terms of the ongoing pregnancy rate (odds ratio = 0.921, 95% CI 0.667 to 1.274). This finding definitively confirms our previous observations regarding the unimpaired potential of vitrified oocytes to develop into competent embryos capable of generating ongoing pregnancies in a proportion comparable to that of fresh oocytes.
Most of the difficulties posed by fresh donations, such as long waiting lists, the need for donor/recipient synchronization, and the lack of quarantine, can be overcome by oocyte cryobanking. Stored oocytes are available anytime they are needed, significantly alleviating donation logistics.
The benefits of oocyte cryostorage have also been demonstrated in autologous in vitro fertilization (IVF) cycles (8-10) leading to high cumulative pregnancy rates (11). Rienzi and coworkers have mirrored our findings on embryo quality and clinical outcomes in a prospective, randomized sibling-oocyte study conducted with infertile patients undergoing own-oocyte IVF cycles (9). The consistency and reliability of oocyte vitrification for this population was further demonstrated in a multicentric study (12) . Additionally, important findings regarding the number of oocytes vitrified, the patient's age, and the developmental stage of the embryo at the time of transfer have been published and have proven useful for patient counseling (12) . Oocyte vitrification has also been suggested to be an interesting therapeutic alternative for low responders (13), improving outcomes for a group that has been very difficult to treat successfully, and may even save patients the disappointment of failure after IVF cycles with a poor response using fresh oocytes (14) .
The extensive research carried out to date has laid the groundwork for the establishment of successful protocols for extremely efficient oocyte cryopreservation. These preservation programs have provided a viable alternative that avoids the downside of an unfavorable uterine environment resulting from administration of exogenous gonadotrophins during controlled ovarian hyperstimultation (15-18).
The research described here has fundamentally changed the clinical landscape and strongly supports the position that oocyte vitrification offers advantageous clinical results in diverse populations, opening up a wide range of possibilities in the field of ART.
all be the same. The reality is that there is not uniform intensity for the SNPs on a single chromosome and individual SNPs may be assigned copy numbers of one, two, or three. This is overcome by application of a Gaussian smoothing algorithm that evaluates the intensities amongst adjacent SNPs and averages them to enhance accuracy. However, the smoothing algorithms used for conventional karyotyping of the cell lines or clinical samples, where hundreds of millions of cells are available, do not function well following whole genome amplification of a single cell.
The optimal smoothing distance was determined on cells with known karyotypes. It was important to validate smoothing on chromosomes that were monosomic and trisomic, and not just disomic. Tolerances were established for the level of discordance amongst individual SNPs on a single chromosome. The upper limit of discordance, meaning the percentage of SNPs on a given chromosome that produce varying results, was established for each chromosome. If that level was exceeded, the assay was deemed "non-concurrent" and the result considered unreliable. The non-concurrent rate per chromosome should be <0.1% and per cell should be <2%. These data were all generated on samples where the karyotype of the cell being tested was known. Functionally, this is starting with the answer and working backwards; a critical step in the process, but far from sufficient to validate the assay.
In the second phase, the prospective blinded evaluation, the testing algorithm was applied to blinded samples. The accuracy per chromosome was >99.9%. More importantly, the overall accuracy of single cell aneuploidy screening using this methodology was 98.6%.
Analyses of Single Cells from Arrested Embryos
In the third phase, individual cells from arrested, cleavage-stage embryos were evaluated. Given the underlying mosaicism, there was no expectation that the results would be uniform. However, when discrepancies occurred, it was logical that they would typically involve reciprocal errors of the same chromosomes. For example, a trisomy X in one cell might be accompanied by a monosomy X in another cell from the same embryo. Additionally, the level of non-concurrence of the SNP assignments on each chromosome should be similar to that found with the cell line samples.
This prospective blinded assessment indeed found non-concurrence rates similar to those in single cells taken from cell lines, indicating similar accuracy levels. Additionally, the majority of the errors were reciprocal, which was highly reassuring.
This study provided the foundation for validating clinical embryonic aneuploidy screening, but represents only the first of several critical steps. The predictive values of both euploid and aneuploid results cannot be determined solely in the laboratory. Clinical studies assessing those predictive values as well as the overall impact on implantation, delivery rates, and clinical decision-making were now possible.
CliniCAl STuDieS eMPOWeReD By SnP ASSAy
DNA Fingerprinting SNP arrays provide data on genetic polymorphisms that may be used for DNA fingerprinting (4). This provides a unique opportunity for a paired, randomized controlled trial (RCT) of sibling embryos since two embryos could be simultaneously transferred and resulting fetuses or newborns could be precisely linked to the embryo from which they developed. This has enabled powerful studies on the impact of oocyte vitrification (5), cleavage, and blastocyst stage embryo biopsy (6) , and other ongoing clinical trials.
Benchmark for Alternative Methods of CCS
A validated method for comprehensive chromosome screening (CCS) provides an opportunity to test other screening methodologies. For example, SNP arrays were used to demonstrate that FISHbased blastomere analysis is inconsistent (7) and poorly predictive of aneuploidy in the developing blastocyst (8) , indicating that FISH is limited by more than just the inability to test all 24 chromosomes. In addition, it served as a standard when developing quantitative real-time (q)PCR (9) and next generation sequencing based methodologies (10) . Finally, SNP arrays were used to demonstrate significantly reduced concurrence of CCS by array comparative genomic hybridization compared to qPCR, based on blinded analysis across multiple laboratories (11) .
Clinical Trials
Validation of the assay and DNA fingerprinting was followed by a prospective trial to determine the predictive value of euploid and aneuploid screening results for actual clinical outcome (12) . Embryos selected by standard morphological criteria were biopsied and immediately transferred prior to any analysis of the sample. SNP array predictions of aneuploidy and euploidy were compared to the actual clinical outcomes and used to directly calculate the predictive values of the assay. Approximately 4% of embryos designated as aneuploid actually implanted and developed euploid fetuses. Subsequent improvements have reduced this number to <2%. Embryos that screened euploid were more than twice as likely to implant and deliver. This study (12) met a critical requirement for validating embryonic aneuploidy screening-to directly measure the predictive values of an aneuploid result so that the risk for discarding a euploid embryo may be specifically determined.
Given the demonstrated equivalence of qPCR-and SNP-arraybased CCS described above, SNP arrays indirectly provided an opportunity to test qPCR clinical efficacy in subsequent RCTs. The first RCT demonstrated that, in women under the age of 42 with no more than one prior failed IVF cycle and a normal ovarian reserve, CCS improves the success of IVF (13) . A second trial further established the utility of CCS by demonstrating equivalent success rates with the transfer of a single euploid blastocyst compared to the transfer of two untested blastocysts, while eliminating twins (14) and improving obstetrical outcomes (15) .
ADDiTiOnAl APPliCATiOnS
SNP array CCS has also been demonstrated effective at identifying sub-chromosomal imbalances associated with reciprocal translocations (16, 17) . These studies showed the importance of evaluating aneuploidy of all 24 chromosomes in parallel with analysis of the derivative chromosomes from the translocation, since many otherwise balanced/normal embryos were aneuploid for chromosomes not involved in the translocation.
SNP arrays have also provided an opportunity to use loss of heterozygosity to address the clinical relevance of uniparental disomy [found to be extremely rare in the blastocyst (0.06%)], to confirm the parthenogenetic status of embryos derived after swapping nuclei between oocytes to eliminate mitochondrial DNA variants (18) , to investigate the parental origins of aneuploidy using genotype comparisons (19) , and to confirm the genetic status of human embryos derived from somatic cell nuclear transfer (20) .
What Is a "Normal" Semen Analysis?
David S. Guzick
Reference values for semen characteristics have been based on the distribution of values in fertile men. In an effort to provide more meaningful reference values, in 2001 members of the National Institutes of Health's (NIH) Reproductive Medicine Network (RMN) reported values for semen measurements based on a comparison of fertile and infertile men. Instead of a single value for each semen measurement that would distinguish between "normal" and "abnormal," data analysis yielded ranges of values that delineated three groups-fertile, indeterminate, and subfertile. These results can be more meaningfully applied in clinical practice and research than previous measurements.
inTRODuCTiOn During a standard infertility evaluation, both male and female partners undergo a series of diagnostic tests in an effort to shed light on etiology (1). In the male partner, a semen specimen is typically evaluated for sperm concentration, motility, and morphology. The results are presented to the patient, usually with a statement about whether each of these parameters is "normal." But what is "normal"? Most clinicians refer to values published in the World Health Organization (WHO) Manual for Semen Analysis, the last edition of which was published in 2010 (2) . Recognizing that there is substantial overlap in sperm parameters between fertile and infertile men (3) (4) (5) , beginning with the 1999 edition of the WHO manuals, the nomenclature for semen characteristics was changed from "normal" to "reference" values.
Two prospective studies of semen parameters and fertility among couples who discontinued contraception, published in 1998 (6) and 2000 (7), indicated that a reexamination of the WHO criteria was warranted. In an effort to provide more meaningful reference values, the NIH Reproductive Medicine Network (RMN) conducted a study to identify values for semen measurements that best discriminate between fertile and infertile men (8) .
MeThODS
In the RMN study, two semen specimens from each of the male partners in 765 infertile couples and 696 fertile couples were evaluated using uniform and rigorous methods. The infertile couples were drawn from a randomized clinical trial in which the female partners all had normal results in an infertility evaluation (9) . Fertile men (controls) were recruited from prenatal classes at the same hospitals in which the infertile couples were recruited. Within each of nine RMN sites, fertile couples were frequency matched to infertile couples according to the five-year age groups of both partners.
Technicians from each of the nine RMN sites attended training sessions in semen analysis at a central laboratory. Semen specimens were stained at the clinical sites and shipped to the central laboratory for assessment of sperm morphology by a single technician, trained Table 2 . Odds ratios for infertility for combinations of sperm measurements. The ranges of the sperm measurements were defined by the thresholds derived from CART analysis. The reference group for the odds ratios is the mean with all three measurements in the fertile range. CI denotes confidence interval. Table 1 . Fertile, indeterminate, and subfertile ranges for sperm measurements using CART analysis and the corresponding odds ratios for infertility. CI denotes confidence interval.
by the developer of a strict morphology assessment (10) . All data were then sent to a central site for data coordination and statistical analysis. Classification and regression tree (CART) analysis (11) was used to estimate thresholds for each sperm measurement that would discriminate between fertile and infertile men. Two thresholds were estimated for each sperm characteristic: one between the subfertile and indeterminate ranges, and the other between the indeterminate and fertile ranges.
ReSulTS
Infertile men were slightly older than fertile controls (mean age: 34.7 vs. 33.5, p<0.001), and were more likely to be white (91.0% vs 85.2%, p<0.001) and to smoke (17.9% vs. 12.5%, p=0.02), but were less likely to have completed college (55% vs. 64%, p<0.001). As shown in Table 1 , the CART-defined subfertile range for sperm measurements was a concentration of less than 13.5 million per milliliter, less than 32% motility, and less than 9% normal morphology. Table  1 also shows CART-identified thresholds that identify the indeterminate and fertile ranges, and associated odds ratios. Table 2 shows that the odds of infertility increase with an increasing number of sperm measurements in the subfertile range. An increase by a factor of two to three in the likelihood of infertility when one sperm measurement was in the subfertile range can be compared with an increase by a factor of five to seven in the risk of infertility when two sperm measurements were subfertile, and an increase by a factor of 16 when all three measurements are subfertile.
The frequency distributions of fertile and infertile men with regard to the three sperm measurements are shown in Figure 1 . Overall, the degree of overlap between fertile and infertile men is striking. Indeed, approximately equal proportions of fertile and infertile men had values in the indeterminate ranges of the three sperm measurements. There was an excess of infertile men with values in the subfertile ranges of these variables, and a corresponding excess of fertile men with values in the fertile ranges.
The area under receiver-operating-characteristic (ROC) curves (12) , which assesses the level of discrimination between fertile and infertile men, was significantly greater for morphology (0.66) than for concentration (0.60; p<0.001) and motility (0.59; p<0.001).
DiSCuSSiOn AnD uPDATe
A case can be made that the case-control methodology used in the RMN study is the best of an imperfect set of options. Follow up of couples who have discontinued contraception has the advantage of prospectively defining couples as fertile and infertile, but such an approach requires large samples, given the low incidence of infertility, and is complicated by the unknown extent of female infertility among the couples so defined as infertile. To date, reference values from such a methodology have not been proposed.
The WHO manual uses a statistical cut-point among fertile men, defined as the 5th percentile in the last edition. Such men are at the statistical tail of the normal distribution of fertile men, but they are still fertile. Using a population of fertile men to predict male infertility makes little sense, biologically or methodologically. Moreover, the databases from which cut-points were chosen in the first four editions were constrained by imprecisely defined reference populations of fertile men, and there was variability in the standards and protocols among andrology laboratories (13) . Reference values defined in the latest edition are based on a pooled database with improved laboratory consistency and a better characterized group of recent fathers. The 5th percentile of semen characteristics among these fertile men were: sperm concentration <15 million per milliliter; motility <40%; and normal morphology <4%.
Interestingly, the WHO cut-point for sperm concentration is quite close to the cut-point found in the RMN study that separated subfertile from indeterminate. Comparing fertile and infertile men, the RMN study identified a somewhat lower threshold for motility (32% vs. 40%). This is reflected in Figure 1 , which shows no difference between fertile and infertile men in the range of 32%-42% motility. Additionally, Figure 1 shows a clear difference between fertile and infertile men in the range of 5%-8% normal morphology, which justifies an RMN-defined cut-point for morphology that is higher than the WHO manual. Semen characteristics are, biologically, continuous variables. Whether they be sperm measurements such as concentration, motility, and morphology, or sperm function tests such as zona binding assays, egg penetration tests, acrosome reaction testing, or others, no measurement has a clear cut-point that separates fertile from infertile. Thus, clinicians cannot convey with certainty to an infertile couple that a semen measurement below a given threshold value is responsible for their infertility, nor that a value above such a threshold excludes a male factor etiology. This is essentially a probabilistic matter. In the RMN study, to capture this idea, instead of a single value for each semen measurement that would distinguish between "normal" and "abnormal," we defined the two values that best delineated three groups: fertile, indeterminate, and subfertile.
Since these values have been defined by comparing fertile and infertile men, they provide ranges that can be meaningfully applied in clinical practice and research. Preeclampsia remains a major cause of maternal and fetal morbidity and mortality worldwide. We have previously suggested that aberrant vascular endothelial growth factor signaling due to excess circulating soluble fms-like tyrosine kinase 1 plays a causal role in the pathogenesis of preeclampsia. This article summarizes the key pathophysiological consequences of these angiogenic abnormalities and discusses our efforts to translate this knowledge into novel diagnostic and therapeutic strategies.
Circulating Angiogenic Factors and the Risk of Preeclampsia
inTRODuCTiOn As a leading cause of premature birth and maternal and infant mortality worldwide, preeclampsia remains a tragically unmet public health challenge. Preeclampsia and related hypertensive disorders conservatively cause over 75,000 maternal and 500,000 infant deaths globally each year (www.preeclampia.org) mostly in developing countries. The mechanisms that initiate preeclampsia in humans have long been elusive, leading to its description in medical textbooks as an idiopathic "toxemia" of pregnancy whose definitive treatment remains delivery of the placenta. Nearly a decade ago, we proposed that elevated plasma soluble fms-like tyrosine kinase (sFlt1), an anti-angiogenic protein, and low levels of placental growth factor (PlGF), a pro-angiogenic protein, were key pathophysiological characteristics of preeclampsia (1, 2) and showed robust correlations with disease presence and severity (3). Moreover, alterations in these angiogenic factors were noted prior to onset of clinical signs or symptoms (1, 4) . In addition, we demonstrated that alterations in circulating sFlt1 may explain a number of risk factors for preeclampsia such as multiple gestation, trisomy 13, nulliparity, and molar pregnancies (5). These findings led us to hypothesize that preeclampsia is an anti-angiogenic state due to excess circulating sFlt1 (6) .
BiOlOgy OF AnTi-AngiOgeniC STATe in PReeClAMPSiA
In 2003, we identified upregulated sFlt1 mRNA in preeclamptic placentas (3). sFlt1 protein, a splice variant of the vascular endothelial growth factor (VEGF) receptor Flt1 or VEGFR1, is made by the syncytiotrophoblast layer of the placenta and is secreted into maternal circulation (7), inhibiting VEGF signaling in the vasculature (Fig. 1) . Circulating sFlt1 levels are markedly increased in women with established preeclampsia, while free VEGF levels are decreased (3) even prior to onset of clinical signs and symptoms (8) . Furthermore, removal of sFlt1 or addition of exogenous VEGF can reverse the anti-angiogenic phenotype noted in preeclamptic plasma (3, 9) . Heterologous expression in rodents produces a syndrome of hypertension, proteinuria, and glomerular endotheliosis in the kidney resembling human preeclampsia (3, 10, 11) . Recombinant VEGF therapy or lowering of sFlt1 ameliorates the preeclampsia phenotype in rodent models (10, 12, 13) . Reduction of VEGF levels by 50% in the glomeruli using genetically modified mice leads to proteinuria and glomerular endothelial damage that resemble preeclampsia (14) . Furthermore, VEGF antagonists, used in cancer patients, can produce a preeclampsia-like phenotype including hypertension, proteinuria, and cerebral edema that is often noted in severe preeclampsia (15) (16) (17) . These data support the hypothesis that inhibition of VEGF signaling in an adult may lead to preeclampsia-like signs/symptoms.
The studies on sFlt1 and VEGF in preeclampsia biology have also led to new insights into basic biology of vascular and placental homeostasis in health and disease. The microvasculature of organs affected in preeclampsia such as the glomeruli and hepatic sinusoidal vasculature are more permeable due to the presence of intracellular perforations referred to as fenestrations. While it was previously known that VEGF induces endothelial fenestrae in culture (18) , experimental data in VEGF knockout mice demonstrated that fenestral density is regulated by constitutive expression of VEGF (14) . Therefore it is not surprising that the microvascular damage in preeclampsia is largely concentrated in vasculature that constitutively express VEGF and that loss of endothelial fenestrae in preeclampsia is due to excess circulating sFlt1. While the placenta is the major source of sFlt1 production, recent studies have suggested that syncytial knots (degenerating syncytiotrophoblast tissue) in the placenta are the major site of sFlt1 production (19) . These syncytial knots easily detach from the syncytiotrophoblast, resulting in free multinucleated aggregates (50-150 mm diameter) laden with sFlt1 protein and mRNA, which are secreted into the maternal circulation. Studies using autopsy material have confirmed that shed syncytial knots contribute to circulating sFlt1 in preeclampsia (20) .
It is likely that other synergistic anti-angiogenic proteins such as soluble endoglin and semaphorin 3B may also contribute to the pathogenesis of preeclampsia (21, 22) . Patients presenting with high levels of both soluble endoglin and sFlt1 had a more severe and premature form of the disease (21, 23) . Animals exposed to high soluble endoglin and high sFlt1 developed the most severe features of preeclampsia, including cerebral edema (21, 24) . More research into the role of these synergistic factors in preeclampsia is needed.
BiOMARkeR STuDieS in PReeClAMPSiA
Although VEGF is secreted, it acts as a juxtacrine or autocrine growth factor locally, and circulating VEGF levels are relatively low during pregnancy (<10 pg/mL). Furthermore, measurement of VEGF in serum is compromised by platelet VEGF release during clotting and hence circulating VEGF is not a useful biomarker for clinical use. As a surrogate of VEGF impairment, placental growth factor levels (PlGF) in the plasma has emerged as an attractive biomarker. PlGF, a VEGF family member, is a pro-angiogenic protein abundant during pregnancy, which binds to the Flt1 receptor, but not other VEGF receptors such as the kinase insert domain receptor (KDR). As sFlt1 levels rise, free PlGF levels drop, and the sFlt1:PlGF ratio correlates with preeclampsia phenotypes (25, 26) . Working with industry partners, we and others have developed highly sensitive, specific, and robust high throughput assays to quantitate levels of sFlt1 and free PlGF in plasma and serum (27) (28) (29) .
Several groups have demonstrated that sFlt1 and PlGF levels can be used to differentiate preeclampsia from diseases that mimic preeclampsia such as chronic hypertension, gestational hypertension, kidney disease, and gestational thrombocytopenia (30) . We led a large prospective study that demonstrated that the plasma sFlt1:PlGF ratio at presentation predicts adverse maternal and perinatal outcomes (occurring within two weeks) in the preterm setting. This ratio alone outperformed standard clinical diagnostic measures including blood pressure, proteinuria, uric acid, and others. Importantly, sFlt1:PlGF levels in the triage setting correlated with preterm delivery, an observation that has now been confirmed by several groups (31) (32) (33) . In addition, we demonstrated that women diagnosed with preeclampsia, but with a normal angiogenic profile, are not at risk for adverse maternal or fetal outcomes (34) .
TheRAPeuTiC STuDieS
Human and animal studies as outlined above have strongly suggested that targeting the sFlt1 pathway may be a viable strategy to prevent or treat preeclampsia. Below are some strategies that have been evaluated in either preclinical or early clinical studies.
Therapeutic Apheresis sFlt1 has a large volume of distribution, and circulating plasma levels represent less than 20% of the total body sFlt1 burden (35) . We hypothesized that a selective adsorption column such as dextran sulfate (a polyanionic derivative of dextran) could augment sFlt1 removal. Dextran sulfate binds sFlt1 efficiently (36) and these columns have been used previously to bind apolipoprotein B-containing lipoprotein LDL in pregnant patients with familial homozygous hypercholesterolemia without adverse consequences to mother or fetus (37) . In a proof-of-concept study, we demonstrated that a ~30% reduction in circulating sFlt1 levels using dextran sulfate apheresis may be sufficient to ameliorate preeclamptic signs and symptoms and prolong pregnancy duration. We have successfully extended (in a single arm unblinded study) three preeclamptic pregnancies by two to four weeks, all of which resulted in healthy deliveries with no neonatal or maternal morbidity (36) . During treatment, sFlt1 levels were lowered by ~30% on average, indicating that modestly lowering circulating sFlt1 levels may be sufficient to successfully prolong preeclamptic pregnancies.
Relaxin and Statins
Experimental studies suggest that the hormone relaxin, a naturally occurring ovarian hormone, may be used to ameliorate preeclampsia by improving vascular compliance and upregulating locally produced VEGF (38) . A phase I study to test the safety of human relaxin in women with preeclampsia is ongoing (39) . Compounds that upregulate pro-angiogenic factors such as statins also have been demonstrated to reverse preeclampsia in animal models (11) . A clinical trial to test the safety of statins in women with established preeclampsia has been initiated in the United Kingdom (40) .
SuMMARy
During the past decade, epidemiological, experimental, and therapeutic studies from several laboratories have provided compelling evidence that an anti-angiogenic state due to excess circulating sFlt1 and related angiogenic proteins leads to preeclampsia. Further work on the regulation of sFlt1 production may improve our understanding of the fundamental molecular defect in preeclampsia. We anticipate that in the ensuing decade, these molecular discoveries will lead to improvement of care of patients suffering from preeclampsia and its devastating complications.
Disclosures: SAK is co-inventor of multiple commercial patents related to diagnosis/treatment of preeclampsia that have been licensed to multiple companies. SAK has served as a consultant to Roche, Beckman Coulter, and Siemens Diagnostics, and has financial interest in Aggamin LLC. RT is co-inventor on patents related to licensed biomarkers in preeclampsia. RT also discloses financial interest in Aggamin LLC.
Functional ovaries are necessary in mammalian females for propagation of the species and maintenance of the hormone milieu. Throughout most of the postnatal life of a female, oocytes-the female germ cells-are encased in somatic cells in structures called follicles. The resting pool of follicles, called primordial follicles, either die or are recruited into the growing pool of more developed follicles. Although there is much debate about postnatal oocyte stem cells, it is believed that the rate of demise of primordial follicles determines the reproductive longevity of an individual within a species. While there are many mutations that have been identified that disrupt female fertility in model organisms (mainly mice), few mutations in ovary-specific genes have been identified in women with fertility problems. However, new strategies for genome sequencing may help to identify causative fertility associated mutations. Effective treatments exist for all types of ovarian failure, though ovulation dysfunction is more difficult to detect and empirical treatments have less certain benefits.
The BASiC SCienCe
Over the last 25 years, we have witnessed amazing and rapid advances in our understanding of the genetics of mammalian reproduction, in particular the genes and factors important for ovarian development and physiology [reviewed in (1) (2) (3) (4) (5) ]. In large part, this progress has been possible because of breakthroughs in DNA sequencing and transgenic mouse technology. Knockout mouse strategies, developed in the late 1980s and early 1990s, allowed researchers to address the question, "What is the essential role of a gene product?" Prior to this point, the reproductive genetics community relied on spontaneous mutations or N-ethyl-N-nitrosurea (ENU) mutagenesis-a challenging process akin to finding a proverbial needle in a haystack. Embryonic stem (ES) cell technology allowed for the reverse genetics approach in which precise mutations could be created to disrupt a gene and subsequently elucidate its function.
This technology has permitted identification of over 100 proteins that function in the formation of female embryonic germ cells, at every stage of ovarian folliculogenesis, in post-ovulation events, and at various stages of meiosis and DNA repair. These pioneering studies prompted work in other mammalian species, including sheep, with relevant and important translational follow up in humans. Some of the pertinent studies will be described in depth below.
geRMline STeM CellS
The pioneering transgenic mouse studies of Brinster and Palmiter (6) , and others led not only to the advances in mouse reproductive genetics, but also to advances in oocyte and embryo culture conditions for human assisted reproduction [elegantly reviewed in (7)] and in manipulation of the male germline (8) . Spermatogonial stem cell transplantation techniques identified factors required for the maintenance of male stem cells in an undifferentiated state and also uncovered genes that mark the differentiated state (8) . More recently, other groups have attempted to identify and define female germline stem cells, generating enormous controversy in the literature, the lay press, and at scientific meetings. While not wanting to join in the controversy, especially since there may be some differences between animal models and humans, we will comment on two intriguing studies published recently. First, Liu and colleagues (9) used a genetic trick to make DDX4-positive germ cells in the postnatal ovary, and thereby follow the differentiation and proliferation of these cells over time. The authors could not detect mitotically active germline precursors, in contrast to the previous studies in mice (10) or humans (11) . Second, Saitou and colleagues (12) differentiated mouse XX ES cells and induced pluripotent stem (iPS) cells into cells resembling primordial germ cells (PGCs), reconstituted these cells with gonadal somatic cells, and showed that they could undergo meiosis. In vivo, these cells with meiotic potential could develop to the germinal vesicle stage and could give rise to fertile offspring when subjected to in vitro maturation and fertilization. Thus, oocyte precursors could be created from pluripotent stem cells and could be manipulated for fertilization.
The above studies and other exciting research being performed in defining sex divergent steps in the differentiation of PGCs and the intrinsic and extrinsic factors necessary for prenatal entry into and arrest of meiosis will continue to influence the scientific pursuit of the elusive oocyte stem cell. These studies will also aid in the in vitro production of functional oocytes from human ES cells and/or iPS cells.
BiDiReCTiOnAl COMMuniCATiOn DuRing FOlliCulOgeneSiS
Understanding the control of the recruitment of follicles into the growing pool has been an actively pursued area of research. The Eppig and Nalbanov laboratories have postulated that oocyte-secreted factors could influence somatic cell function in vitro [reviewed in (1) ], and later work of Eppig showed that the oocyte dictated the phenotype of the postnatal granulosa cells (13) . In 1996, knockout mouse studies from the Matzuk laboratory uncovered for the first time the identity of one of these oocyte-secreted germline factors, growth differentiation factor 9 (GDF9), a member of the transforming growth factor β (TGF-β) superfamily (14) . Mice lacking GDF9 showed a Figure 1 . Follicular, ovarian, and endometrial ultrasonographic measurements at the beginning and end of the one-month baseline period and at their maximum during r-metHuLeptin treatment. Each symbol represents one subject. Reprinted with permission from (16). block in folliculogenesis at the primary follicle stage, and later studies identified an oocyte-secreted paralog, bone morphogenetic protein 15 (BMP15), which also influences fertility in mice, sheep, and women (5) . More recent studies demonstrated that mouse and human GDF9:BMP15 heterodimers are far more biopotent than active homodimers (10-30-fold higher activity in mice; ~3,000-fold in humans) (15) . However, oocyte-secreted growth factors are only one-half of an ongoing bidirectional dialog that regulates key metabolic synchrony of oocytes and granulosa cells throughout folliculogenesis (see also page 13). The implications of these studies are far-reaching for animal and human fertility, and include the development of new, defined culture media supplemented with cocktails of oocyte and granulosa cell proteins and metabolites that take advantage of this crosstalk.
PiTuiTARy COnTROl OF OVARiAn FunCTiOn
Follicle-stimulating hormone (FSH) and luteinizing hormone (LH) are key regulators of ovarian function (16) . Mice lacking FSH and women with homozygous mutations in the FSHβ or FSH receptor gene are infertile secondary to blocks in folliculogenesis at the multilayer preantral follicle stage. Mice or women with mutations in the LHβ or LH receptor genes have blocks prior to ovulation resulting in infertility. The ability to predict defects at the hypothalamic or pituitary levels based on alterations in serum FSH or LH levels has enabled the identification of other genes that are important regulators of FSH and LH, and that indirectly influence gonadotropin synthesis (16) . An understanding of these key ovarian regulators has been critical for assisted reproduction.
The CliniCAl SCienCe
We will now shift focus to highly cited articles that relate to clinical interventions that have improved (or replaced) ovarian function in an infertile population ( Table 1 ). The choice is highly subjective, but the goal is to include articles that have led to a paradigm shift in the treatment of female infertility. We will cover treatments for the most common causes of ovulation failure, as well as lesser ovulatory problems such as those found in undiagnosed or unexplained infertility. The World Health Organization (WHO) provides a schema for ovulation failure with three categories (based on hypothalamic/ pituitary and ovarian function): Type I (hypogonadotropic, hypoestrogenic), Type II (normogonadotropic, normoestrogenic), and Type III (hypergonadotropic, hypoestrogenic).
WHO Type I: Anovulation-Hypothalamic Amenorrhea
Hypothalamic amenorrhea can arise from genetic conditions leading to failure of the GnRH neurons to develop or migrate to the hypothalamus or from disruption of genes relating to onset of puberty. There are also common acquired conditions associated with stress, excessive exercise, and loss of body fat/weight (i.e., anorexia nervosa or exercise-induced amenorrhea), which can cause hypothalamic shutdown and downstream loss of ovarian function. While treatment with gonadotropins effectively bypasses the hypothalamic GnRH pulse generator and directly stimulates follicular development, the factors leading to the hypothalamic failure remain in doubt. Cessation of activity and regain of weight should cure the condition, but no high-quality clinical trials have yet demonstrated this.
The study of Welt et al. (17) looked at the effects of recombinant leptin administration on ovarian function in women with hypothalamic amenorrhea. The intervention group was observed without treatment for one month, then administered recombinant leptin for up to three months. A control group received no treatment. Five of eight patients in the intervention group either ovulated or had some resumption of ovarian activity (Fig. 1) . None of the control subjects or intervention subjects during the initial observation period showed any change. This provided evidence that peripheral fat status was critical to maintaining reproductive function and supported studies that a critical amount of fat mass is necessary to initiate menarche.
WHO Type II: Ovulatory Dysfunction-Polycystic Ovary Syndrome
A study of Legro et al. (18) occurred at a time of great debate as to the best treatment for polycystic ovary syndrome (PCOS), a heterogeneous condition of hyperandrogenism and chronic anovulation, with characteristic polycystic ovaries filled with preantral follicles. PCOS was viewed by some as a metabolic syndrome due to dimin- The time course and quantitative change in circulating concentrations (Mean ± SE) of luteinizing hormone (LH), follicle-stimulating hormone (FSH), estradiol (E 2 ), and progesterone (P) during the menstrual cycle of four normal women treated with a GnRH agonist for three days after menses onset (hatched box, left). Data were centered around the midcycle gonadotropin peak (day 0). Reprinted with permission from (25) .
ished insulin action-requiring primary treatment with insulin-sensitizing effects-and by others as a reproductive abnormality with inappropriate gondadotropin secretion and corresponding altered ovarian steroidal production, and lack of development of functional follicles resulting in anovulation. The study examined the effects of ovulation-inducing agents: clomiphene alone vs metformin alone vs their combination in infertile women with PCOS, using a double blind double dummy design.
Contrary to expectations, clomiphene was markedly superior to metformin achieving a twofold higher live-birth rate, with the combination offering a further marginal but non-significant improvement. Importantly, the quality of ovulation differed depending on ovulationinducing agent: the improved fecundity and ovulation rates on clomiphene were associated with increased body weight, waist circumference, and insulin levels from baseline, implying that improvement in these factors were not as critical to restoration of ovulation in these women as previously thought. This study served to justify the search for ovulation-inducing agents that work primarily by altering ovarian steroid feedback to the hypothalamic pituitary axis, such as aromatase inhibitors that block the conversion of excess androgens to bioactive estrogens.
WHO Type III: Anovulation Age Related to Diminished Ovarian Reserve
Primary ovarian insufficiency can be due to genetic conditions such as Turner's Syndrome or single gene defects such galactosidase deficiency or mutations acquired from exposure to radiation or alkylating agents during cancer treatment. Further, while Type III anovulation occurs relatively rarely, all women experience an age-related decline in ovarian function, with increasing rates of embryo aneuploidy and miscarriage, culminating in the complete loss of ovulation and menses at menopause. While preservation of fertility is a rapidly expanding preventive treatment option, there have been no real advances in restoring ovarian function in women with age-related ovarian insufficiency. A breakthrough occurred when it was shown that embryos created from donor oocytes could be placed in the uterus of a woman with ovarian insufficiency whose endometrium had been rendered receptive to embryo implantation using sex steroid treatment. Case reports describing embryo flushing in inseminated oocyte donors (19) and IVF performed using donor oocytes (20) provided evidence in support of this procedure.
The broader clinical implication, built upon this evidence, was the extension of this therapy to women with advanced age and infertility due to what is now described as diminished ovarian reserve (DOR). Sauer et al. (21, 22) studied women over 40 with DOR, finding that implantation of donated oocytes yielded pregnancies and live-birth rates markedly superior to expected fertility rates based on age. Manipulation of hormone levels to prepare the uterus for implantation is shown in Figure 2 . Rates of pregnancy after oocyte donation routinely exceeded those after standard IVF in women of all age groups in registries throughout the world. Such high success rates in a group that had previously experienced such dismal results reset Oocyte donation is an effective treatment for women with diminished ovarian reserve with live-birth rates similar to those with primary ovarian insufficiency, suggesting uterine function is not agedependent.
Ovulatory Dysfunction
Acquired luteal phase defect 25
A luteal phase defect, characterized by a shortened luteal phase with inadequate circulating serum progesterone levels could be induced by the administration of a GnRH agonist in the early follicular phase in normally ovulating women.
Subtle Ovulatory Dysfunction
Unexplained infertility 26
Empiric treatment with the ovulation induction agent clomiphene or with unstimulating intrauterine insemination is no better than expectant management for couples with unexplained infertility.
expectations for subsequent therapies. Further, it underscored that the primary effects of aging impacted oocyte quality and number.
OVulATORy DySFunCTiOn-luTeAl PhASe DeFeCTS
Many women with infertility or recurrent pregnancy loss do not present with chronic or sporadic anovulation, but are suspected to have some form of ovulation dysfunction leading to the absence of functional oocytes and/or to implantation failure. Several ovulatory disorders occur within the context of what appears to be regular ovulation, but continue to defy clear definition and diagnosis. These include extremely rare disorders such as luteinized unruptured follicle syndrome, empty follicle syndrome, and more common disorders such as luteal phase defects (LPDs). LPDs, originally described by Georgeanna Jones, are characterized by inadequate corpus luteum function following ovulation, as measured by a variety of parameters including inadequate rise in basal body temperature, secretion of progesterone or its metabolites, an out-of-phase endometrial biopsy, or a shortened luteal phase (23) . Subsequent studies have found this disorder difficult to diagnose largely due to the occurrence of these "abnormalities" in normal, fertile populations (24, 25) . However, the proof of concept for LPD was demonstrated in a classic study by Sheehan et al. (26) in which normally ovulating women (verified by careful monitoring of gonadotropins and sex steroids prior to treatment) were administered a GnRH agonist in the early follicular phase that resulted in a temporary increase in gonadotropin secretion, followed by a decrease in FSH levels and a shortened luteal phase (Fig. 3) . While this was seen at the time as a potential contraceptive, it helped to justify the use of progesterone administration to supplement the luteal phase in IVF cycles where a GnRH agonist had been administered, and was also used to treat women with suspected LPDs.
unexPlAineD inFeRTiliTyeMPiRiC OVulATiOn inDuCTiOn
Unexplained infertility remains the most heterogeneous of infertility diagnoses and contains subclinical etiologies related to ovulatory, tubal, and male factors. Couples often receive empiric therapy which takes a shotgun approach, trying to hit multiple targets with a single shot. Empiric treatment with ovulation-inducing agents such as clomiphene and gonadotropin has two intended goals: to increase the quality of ovulation (difficult to quantify, as noted above with LPDs) and to cause superovulation, which results in multiple mature oocytes and both a greater chance for pregnancy and a higher risk of multiple pregnancies.
The study by Bhattacharya et al. (27) randomized couples with unexplained infertility into three treatment groups (with similar initial pregnancy rates): empiric clomiphene citrate, unstimulated intrauterine insemination (IUI), or expectant management. The trial was unique for the inclusion of the control expectant management group, a "watch and wait" approach not usually regarded as acceptable in an infertility clinical trial. Although subjects in the expectant management group were less satisfied with their participation than others, the trial did meet its enrollment goals. This trial examined the role of subtle, subclinical ovulatory dysfunction in unexplained infertility and, although there was no statistically significant benefit to IUI, it trended better than clomiphene. This study raised the bar for empiric infertility treatments, introducing the requirement that proof of benefit of the intervention over expectant management be shown before acceptance as a clinical treatment. It further underscores the need for better diagnosis strategies in unexplained infertility.
COnCluSiOnS
This review summarizes groundbreaking research that offers hope for new treatments of ovarian disorders that lead to ovulation dysfunction and anovulation. It highlights the critical role of the oocyte in its traditional responsive role to gonadotropins and ovarian factors, but also its newer role in guiding ovarian function. With a greater emphasis on translation of this work to the clinic, we anticipate that the classic treatments of the past will soon be supplanted by newer and better evidence-based strategies. inTRODuCTiOn Infertility impacts the lives of 8% to 12% of couples attempting to conceive for the first time. In roughly half of these cases a male factor is causative yet, surprisingly, in many assisted reproductive technology (ART) clinics the male is not clinically evaluated beyond a routine semen analysis. While most textbooks state that primary infertility in approximately 30% of infertile men is idiopathic, some experts speculate that 50% to 80% of all male infertility results from a (usually undiagnosed) genetic cause. In these patients, no explana tion can be found for their impaired semen quality. In part, this statistic reflects our poor understanding of the basic mechanisms regulating sex determination, genital tract differentiation and development, spermatogenesis, sperm maturation in the genital tract, and the molecular events required for fertilization and early embryonic development; hence, our inability to properly diagnose the cause of the infertility. Indeed, many of the commonly used diagnostic categories for male infertility are descriptive rather than mechanistically based. A diagnosis of non-obstructive azoospermia (NOA), testicular failure, cryptorchidism, or ductal obstruction provides no insight into the molecular cause of the infertility. In this review, we focus on the molecular defects that underlie the congenital genitourinary birth defects associated with infertility, endocrine deficiencies, idiopathic spermatogenic failure, and deficiencies of sperm function.
Infertility: The Male Factor
STRuCTuRAl AnD nuMeRiCAl ChROMOSOMe DeFeCTS ACCOunT FOR A SigniFiCAnT PeRCenTAge OF MAle inFeRTiliTy
Karyotype abnormalities are present in about 6% of infertile men [reviewed in (1)]. With severe spermatogenic deficiency, the incidence of karyotype abnormalities increases. At our tertiary referral clinic at the Baylor College of Medicine, more than 11% of NOA men and nearly 17% of men with male genitourinary birth defects have karyotype anomalies (2) . These anomalies can be numerical and affect only the sex chromosomes-for example, Klinefelter syndrome (46,XXY-46,XXXXY), which accounts for about 14% of all NOA-or structural, affecting the autosomes or the sex chromosomes, including complex chromosomal rearrangements, deletions, duplications, inversions, and translocations. A well-recognized structural chromosome defect causing male infertility is the occurrence of Y chromosome microdeletions encompassing the azoospermia factor (AZF) region, first described in 1995 (3). The Deleted in Azoospermia (DAZ) gene was the first AZF spermatogenesis gene identified within a Y chromosome microdeletion. The AZF region is now further subdivided into smaller segments termed AZFa, AZFb, and AZFc. Sperm are unlikely to be found in men with deletions in AZFa or b, whereas men with AZFc deletions encompassing DAZ have a 75% chance of having rare sperm found on a testis biopsy [reviewed in (1) ]. For AZFc microdeletions, the rare variant having a major effect on spermatogenesis is seen with the b2/b4 deletion, which accounts for about 6% of severe spermatogenic failure, whereas the more commonly occurring gr/gr deletion has a modest affect, doubling the risk of severe spermatogenic failure (4) .
Upon homologous recombination and meiotic segregation, autosomal structural defects, such as Robertsonian translocations, can result in balanced or unbalanced translocations. Infertility can arise due to the production of unbalanced gametes (nullisomic or disomic) resulting in aneuploid embryos or chromosomally unbalanced offspring (5). Thus, before proceeding with ART to attempt to achieve a pregnancy, it is important to know if chromosome anomalies are present in the male patient.
enDOCRine PAThWAyS ARe CRiTiCAl FOR nORMAl FeRTiliTy in MAleS
Although endocrine defects account for only about 1% of all male infertility, the molecular abnormalities that underlie these conditions are increasingly evident. In short, any genetic defect affecting the hypothalamic-pituitary-gonadal axis, steroid hormone biosynthesis and metabolism, steroid hormone receptors and their signaling pathways, peptide hormones and their receptors and associated signaling pathways, or paracrine factors and cytokines and their respective signaling pathways can affect male fertility [reviewed in (6) (7) (8) ].
The best example of the relative complexity of genetic defects that underlie a seemingly discrete infertility phenotype is reveal by the studies of hypogonadotropic hypogonadism by Crowley and others (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . Gene defects causing GnRH deficiency vary in relation to their site of action on the ontogeny of the GnRH neurons and the clinical phenotype observed. For patients with anosmia, neurodevelopmental gene functions that regulate GnRH neuronal migration or olfactory bulb/tract development are affected due to gene deficiencies, such as in KAL1 and NELF. In contrast, GnRH-deficient patients with normosmia may have defects in genes that encode members of the kisspeptin, neurokinin B, and GnRH signaling pathways such as KISS, KISS1R, TAC3, TACR3, and GnRHR. Interestingly, defects in the prokineticin and FGF signaling pathways (FGF8, FGFR1, PROK2/R) are variably present in patients and families with both anosmia and a normal sense of smell within the same pedigree [reviewed in (9) ]. Despite the identification of numerous monoallelic, bialellic, and digenic mutations in the genes above, a molecular cause for slightly less than half of isolated GnRH deficiency remains unknown and a topic of intense investigation. It is clear that even for hypogonadotropic hypogonadism, considerable genetic complexity underlies the causative defects. 
geneTiC AnD genOMiC DeFeCTS in MAle inFeRTiliTy
Using mouse models, investigators were surprised to learn that genes never thought to be involved in male reproductive function, when deleted, cause infertility. One of the most unexpected finds was that loss or pharmacological blockage of testis-expressed taste genes caused male infertility in the mouse (20) . The targeted deletion of TAS1R3, a component of taste receptors, and the gustducin α-subunit GNAT3, lead to male sterility due to immotile sperm with poor morphology (detached or amorphous heads, tails flipped over heads, and multiple kinks and loops in the tails), indicating a potential role in spermiogenesis and sperm maturation (20) .
In 2008, Matzuk and Lamb summarized the gene defects in mouse models and human patients associated with male infertility [see supplement to (7)], and a large number of additional gene defects have since been defined affecting genitourinary birth defects, disorders of sexual determination and differentiation, puberty, spermatogenesis, sperm function, and other aspects of male reproductive health. For example, cationic channel of sperm (CatSper)-the main flagellar Ca 2+ channel in sperm-was shown to play a role in nongenomic progresterone signaling (21) . Upon activation by progesterone, calcium influx triggers hyperactivated motility and the acrosome reaction. While CatSper mutations occur rarely, they can result in severe asthenozoopsermia (22) . Unfortunately, mouse models are not informative, because unlike humans, the CatSper channel in the mouse is not sensitive to progesterone. Nevertheless, there are literally thousands of possible gene defects identified in mice and humans causing male infertility. In the clinic, however, just one gene is analyzed on a routine basis in males with congenital bilateral absence of the vas deferens (CBAVD)-the CFTR gene (cystic fibrosis transmembrane regulatory protein) (23) . CBAVD is a genital form of cystic fibrosis. For patients of North African ethnicity, patients may also be tested for mutations of the Aurora Kinase C gene, specifically the c.144delC mutation (24) . This mutation results in large-headed, polyploid, multi-flagellar sperm, because this protein is necessary for male meiotic cytokinesis. As research continues, additional genetic testing will no doubt become standard of care in the evaluation of the infertile male.
FeRTiliTy PReSeRVATiOn FOR PReVenTiOn OF SeCOnDARy inFeRTiliTy
In the testis, long-cycling isolated spermatogonia, identified by morphological criteria, have been proposed to be testicular stem cells (25) (26) (27) . The pioneering work of Brinster and colleagues demonstrated, with certainty, that these testicular stem cells exhibit the unique properties of prolonged proliferation, self-renewal, generation of differentiated progeny, maintenance of developmental potential, and proliferation in response to injury (28) . Although work in this area is predominantly in rodent models and more recently primates, this represents a research area of significant promise for patients facing secondary infertility.
Spermatogenesis is damaged by exposure to chemotherapeutic agents, radiation, toxic agents, and occupational exposures to gonadotoxins, resulting in secondary infertility. Prolonged periods of azoospermia or severe oligospermia may result. While sterility appears permanent, spermatogenesis may spontaneously recover years after treatment (29, 30) when the surviving reserved stem cells (type A spermatogonia) reinitiate the proliferative and differentiative events required for spermatogenesis. Today, cancer patients should be advised to bank cryopreserved semen prior to potentially harmful treatment. Children who undergo cancer treatment cannot produce an ejaculate for cryopreservation, and even for adults, most couples would prefer a natural conception. Accordingly, application of spermatogonial stem cell isolation and cryopreservation, followed by germ cell transplantation to restore spermatogenesis after recovery from cancer treatment, may provide a very useful approach to preservation of fertility for these cancer patients.
A significant roadblock to translation of these studies to clinical practice has been the concern that the testis may serve as a reservoir for cancer cells (hematological cancers, in particular) and transplantation of spermatogonial stem cells obtained prior to chemotherapy could transmit the malignant cells back into the now healthy recipient. Recently, a novel cell sorting strategy was devised (21) to remove malignant contamination while simultaneously enriching the population of human spermatogonial stem cells. A human to mouse xenotransplantation biological assay was used to define both the spermatogonial stem cell activity and malignant contamination of the enriched cell populations. The development of these separation technologies will be a major advance towards eventual application of spermatogonial stem cell transplantation in the clinic. However, human studies demonstrating safety and efficacy will be needed, as current purities of 98.8% to 99.8% are still insufficient; even small numbers of malignant cells present during hematopoietic stem cell transplantation will prove problematic. Importantly, hematopoietic stem cell transplantation is required to treat a life-threatening condition whereas fertility preservation is an elective procedure [reviewed in (31) ].
Human spermatogonial stem cells can be cultured under conditions that allow them to exhibit pluripotent potential (32, 33) . The cells exhibit properties similar to embryonic stem cells and can produce teratomas when transplanted into immunodeficient mice. The human adult germline stem cells can differentiate into the full range of cell types, including germline cells (32, 33) .
In the future, spermatogonial stem cells will not only offer the promise of seminiferous tubule rejuvenation after exposure to gonadotoxins, but perhaps also the potential to regenerate organs and tissues. Much further in the future, these cells may be used for gene therapy to cure certain Mendalian inherited genetic diseases.
heAlTh RiSkS FOR inFeRTile Men gO BeyOnD TheiR RePRODuCTiVe WOeS
Although it is important to find methods to bypass or overcome severe male factor infertility, to assist severe male factor patients in achieving a pregnancy, bypassing nature's barriers to fertilization by utilizing potential defective sperm for in vitro fertilization by intracytoplasmic sperm injection (ICSI) may have unrecognized consequences for the patient and his offspring. Today we know that Y chromosome microdeletions occur through events that generate isodicentric Y chromosomes, as well as Y chromosomes with deletions, duplications, or inversions. The first report of Y chromosome microdeletions and their association with NOA came from David Page's laboratory (described above) (3), but it has been recognized more recently that these structural defects can be generated by a variety of mechanisms. Indeed, intrachromosomal homologous recombination can generate pseudo-isoY chromosomes and Y chromosome pericentric inversions (34) . At one time, it was thought that about 95% of the Y chromosome (except the pseudoautosomal regions) did not undergo homologous recombination during meiosis. However, as a result of breakpoint hotspots, as well as homologous recombination errors due to amplicons associated with palindromic structures present on the human Y chromosome, Y chromosome microdeletions may occur (35) . These rearrangements can even occur due to amplicons on the short (Yp) and long (Yq) arms of the Y chromosome through intrachromosomal non-allelic homologous recombination (34) .
These structural Y chromosome defects affect the male specific Y and, although other genes not involved in spermatogenesis were affected, the clinical consequence of these defects appeared to predominantly affect spermatogenesis. However, in part due to isodicentric Y chromosome formation and complex rearrangements and deletions/duplications of the Y, about 25% of men with NOA due to Y chromosome microdeletions have a co-existing genomic syndrome, SHOX (short stature homeobox-containing gene) syndrome (36) (Fig. 1) . SHOX syndrome is the most common cause of short stature and results from mutations, microdeletions, or microduplications of the SHOX gene, which is located in the pseudoautosomal region of the sex chromosomes. SHOX is a dosage-sensitive gene that does not undergo X-inactivation. While SHOX syndrome occurs in Turner and Klinefelter syndrome patients (deletion and duplication, respectively), the clinical spectrum varies. The associated Madelung deformity of the forearm and mesomelic disproportion of the limbs develops over time and appears during the second decade of life (or perhaps never). There are a number of other clinical indications (among them scoliosis, microgathia, and muscular hypertrophy of the calves) that are found in some, but not all, SHOX syndrome patients [reviewed in (37) ]. The presence of SHOX deletion or duplication in a subset of men with Y chromosome microdeletions suggests that this co-existing genomic syndrome could be inherited by the male offspring of men conceived by ICSI, although to date there have been no reports of SHOX syndrome in ICSIconceived offspring.
There may be other associated health issues for the NOA male that are clinically unappreciated. Our studies show a 2.9-fold increased risk of cancer in NOA patients (38) . Walsh and colleagues (39) evaluated data on 22,562 partners of infertile couples and showed the risk of testis cancer was nearly threefold higher in infertile men compared with normal men (38) . Jacobsen et al. similarly evaluated more than 32,000 men who had their semen analysed over a 30-year period and found a 1.6-fold increased risk of testis cancer in men with reduced sperm counts (40) . There was also an increased incidence of cancers of the peritoneum and other digestive organs in these men. Walsh and colleagues performed an analysis of their patient cohort and showed that those with male factor infertility were 2.6 times more likely to be diagnosed with high-grade prostate cancer (39, 41) .
Indeed, a comprehensive male infertility evaluation identified a number of significant (and previously undiagnosed) medical pathologies. In a landmark paper by Honig et al., significant medical pathologies were uncovered in 1.1% of 1,236 patients presenting to a male infertility clinic (42) . Ten patients (0.8%) had tumors (six testis, three brain, and one spinal cord) and their findings point to the need for urologic consultation when an infertile couple seeks treatment at an ART clinic. It is believed that there are common etiologic factors for infertility and cancer development, such as deficient DNA repair mechanisms (39, 40, 43) .
COnCluSiOnS
We have witnessed an exponential increase in advances in our understanding of the molecular controls of spermatogenesis and sperm function, as well as increasing definition of the molecular defects associated with infertility in the male. A major challenge that remains is to enhance our abilities to translate these research advances into routine clinical practice. Additionally, it is essential to ensure that every male factor patient has a complete history and physical performed by a urologist or andrologist/endocrinologist, as well as an in-depth assessment of the causes of his infertility. Our goal is to have physicians recognize that there may be other health risks for the infertile male that go beyond their infertility. We thus look with hope towards the future where the research advances of today will be translated to clinical practice resulting in not only restoration of fertility for currently infertile men after gonadotoxin exposure, but perhaps even regeneration of organs and tissues without the ethical constraints that limit embryonic stem cell research today. Importantly, infertile couples must understand that the cause of their infertility may remain unknown. They also need to carefully consider the potential health risks for both the patient and any offspring conceived by ART that go beyond possible birth defects. 
Molecular Interplay in Successful Implantation
ABSTRACT
Embryo implantation in the maternal womb is a fundamental event in mammalian procreation. The phases of implantation are apposition, attachment, and finally penetration of the blastocyst trophectoderm through the uterine epithelium and into the stroma. Both uterine receptivity and blastocyst activation are required for successful implantation. This review briefly highlights the molecular processes responsible for endometrial receptivity, implantation, and decidualization in mice and humans.
inTRODuCTiOn Implantation requires an effective bidirectional communication between the receptive endometrium and an implantation-competent blastocyst. The duration of the window of implantation (WOI) to achieve optimal pregnancy outcome is short-lived. Blastocyst attachment to the uterine lining (luminal epithelium) initiates the implantation process, which is followed by localized stromal cell proliferation and differentiation to generate specialized decidual cells at the site of implantation, a process called decidualization. Appropriate decidualization directs placentation, in which the maternal circulation is brought into contact with the embryonic vascular system, establishing a functional placenta. Maternal resources, filtered across the placental barrier, nourish and protect the fetus. Implantation is the first significant encounter between the mother and embryo, and is crucial for a successful pregnancy.
MOleCulAR inSighTS AnD CliniCAl iMPliCATiOnS OF enDOMeTRiAl ReCePTiViTy
The WOI, a transient interphase between the prereceptive and refractory phases, lasts approximately 24 hours (beginning day four of pregnancy or pseudopregnancy) in mice and three days in humans during the mid-luteal phase of the menstrual cycle (1-3). Understanding the "molecular clock" at play during the WOI could help to identify biomarkers of endometrial receptivity useful for increasing pregnancy rates in in vitro fertilization (IVF) programs or to develop novel contraceptives.
The master regulators for the acquisition of endometrial receptivity are estrogen and progesterone (P 4 ). In mice, the transition from the prereceptive to the receptive phase requires priming with P 4 superimposed with a small amount of estrogen. The P 4 and estrogen nuclear receptors, receptor chaperones, and co-regulators all play cru- cial roles in regulating the WOI. Progesterone receptors (PR-A and PR-B) and estrogen receptors (ERα and ERβ) are expressed in the uterus. Studies in mice have shown that these isoforms serve as the principle modulators during specific stages of pregnancy. ERα (encoded by the Esr1 gene) is the primary mediator of estrogen activity in the uterus during implantation, as the uteri of Esr1 -/-mice are hypoplastic and unable to support implantation (4). Mice missing both PR-A and PR-B are also infertile and have multiple ovarian and uterine defects, although PR-B-deficient mice show normal fertility (5, 6) , indicating that PR-A is the key player in implantation. FKBP52, an immunophilin co-chaperone for steroid hormone nuclear receptors, optimizes PR activity and has profound effects during pregnancy (7, 8) . In the absence of Fkbp52, P 4 signaling and responsiveness are significantly diminished, resulting in implantation failure. Depending on the genetic background of the mice, this functional P 4 resistance can be overcome by exogenous P 4 administration (9). FKBP52 is also expressed in human endometrium (10) .
ER and PR signaling during implantation are executed by juxtacrine, paracrine, and autocrine factors orchestrated by various growth factors, cytokines, lipid mediators, homeobox transcription factors, and morphogens. Mouse models have improved our mechanistic understanding of several factors critical for uterine receptivity and implantation ( Fig. 1 ; also see reviews 1 and 2). Among the growth factors, heparin-binding EGF-like growth factor (HB-EGF) stands out as a major player in mediating embryo-uterine interactions during the attachment reaction in both mice and humans ( Fig.  2; 11-14) . Membrane-anchored HB-EGF expressed in the luminal epithelium functions as a juxtacrine mediator for adhesion of the blastocyst expressing EGF receptors, while soluble HB-EGF influences embryo-uterine interactions in a paracrine manner (1) . Juxtacrine interactions between the luminal epithelium and blastocyst in humans are also mediated by L-selectin ligands and their receptors displayed on the luminal epithelium and blastocyst cell surface, respectively (15) .
Leukemia inhibitory factor (LIF), a member of the interleukin (IL)-6 family of cytokines, is expressed in mouse uterine glands early on day four of pregnancy (the day of uterine receptivity) and in the stroma surrounding the blastocyst upon attachment late on day four (16, 17) . This factor is essential for uterine receptivity and implantation via binding to its receptor, LIFR, and co-receptor, gp130, to activate STAT3 signaling. LIF-gp130-STAT3 signaling is critical to implantation since uterine deletion of the genes encoding gp130 or Stat3 has been shown to cause implantation failure (18, 19) . More recently identified mediators critical for uterine receptivity are muscle segment homeobox genes (Msx1/Msx2); conditional uterine deletion of these genes results in implantation failure ( Fig. 3; 20) .
In some respects, implantation resembles a pro-inflammatory reaction and involves inflammatory mediators. Cyclooxygenase-2 (Cox2), a critical enzyme for prostaglandin (PG) biosynthesis, is expressed in the uterus at the site of implantation (21) (22) (23) . Cox2-derived PGs are thought to participate in implantation since ablation of the Ptgs2 (Cox2) gene leads to infertility (21) (22) (23) . PGs also influence vascular permeability and decidualization in the stromal bed (24) . Cox2-derived prostacyclin (PGI 2 ) activates PPARδ, which appears to influence implantation as Pparδ -/-mice show deferred implantation and compromised pregnancy outcome (22) . Cytosolic phospholipase A2α (cPLA 2α , encoded by Pla2g4a), which generates arachidonic acid for Cox2-generated PG synthesis, is expressed in the uterus similarly to Cox2. Its critical role in implantation is evidenced by deferred implantation and related adverse effects in Pla2g4a
-/-mice, compromising pregnancy outcome (25) .
Lpar3
-/-mice exhibit a similar phenotype to Pla2g4a -/-mice, exhibiting downregulated Cox2 (26; reviewed in 1 and 2).
Among other lipid mediators, endogenous cannabinoid-like compounds (endocannabinoids) and their G-protein coupled receptors Cnr1 (CB1) and Cnr2 (CB2) also play roles in implantation. Endocannabinoids, N-arachidonoylethanolamine (anandamide), and 2-arachidonoyl glycerol (2-AG), bind to CB1 and CB2. Uterine anandamide levels are higher during the prereceptive phase, but decrease during the receptive phase (27) . Similarly increased anandamide levels resulting from deficiency of fatty acid amide hydrolase (FAAH), which degrades anandamide, lead to multiple pregnancy defects, including disruption of on-time implantation (28) . These re- Figure 1 . Signaling network for uterine receptivity and implantation. Hybrid cartoon, based on mouse and human studies, portraying compartment-and cell-type specific expression of molecules and their potential functions critical for uterine receptivity, implantation, and decidualization. Interplay of ovarian P 4 /estrogen-dependent and independent factors in the pregnant uterus in specific compartments contributes to the success of implantation in a juxtacrine/paracrine/autocrine manner. During attachment, interactions between the blastocyst and luminal epithelium (LE) involve ErbB1/4 (blue) and both transmembrane (TM) and soluble (Sol) forms of HB-EGF, as well as L-selectin ligands expressed by the luminal epithelium to L-selectin receptors on the blastocyst. The other critical signaling pathways for uterine receptivity and implantation are also shown. AA, arachidonic acid; COUP-TFII, chicken ovalbumin upstream promoter transcription factor-2; E, estrogens; EC, epithelial cell (luminal and glandular epithelia); ENaC, epithelium sodium channel; ErbB1/4, epidermal growth factor receptor 1/4; GE, glandular epithelium; Hand2, Heart-and neural crest derivatives-expressed protein 2; HB-EGF, heparin-binding EGF-like growth factor; ICM, inner cell mass; KLF5, Kruppel-like factor 5; LPA3, lysophosphatidic acid receptor 3; MSX1, muscle segment homeobox 1; PPARδ, peroxisome proliferator-activating receptor δ; Ptc, Patched; RXR, retinoid X receptor; SC, stromal cell; SGK1, serumand glucocorticoid-inducible kinase 1; Smo, Smoothened; Tr, trophectoderm. Compartment colors: blue, stroma; pink, luminal epithelium; orange, glandular epithelium; purple, epithelium at the attachment site. Adapted from (1) .
sults indicate that a tight regulation of endocannabinoid signaling is critical to uterine receptivity and oviductal transport of embryos (see page 21). Aberrant anandamide levels are also associated with recurrent pregnancy loss and ectopic pregnancy in women (29, 30) .
In humans, receptive status is typically defined by histological characteristics known as the Noyes criteria (31). However, the accuracy and relevance of these criteria have been questioned (32, 33) . Thus, the search is on-going for specific biomarkers that define the WOI. Morphological changes of the endometrial luminal epithelium include modifications of the plasma membrane (34) and cytoskeleton (35) (36) (37) . The presence of pinopodes was proposed as a receptivity marker (38, 39) , but these ectoplasmic epithelial projections are not specific to the receptive state (40) . Biochemical markers such as integrins (41) , MUC1 (42) , calcitonin (43) , LIF (16) (17) , and HOXA10 (44) initially generated interest, but none have proven to be effective in clinical practice.
Microarray technology has advanced the search for biomarkers based on the transcriptomics signature during the WOI (45) . Recent evidence has helped to characterize the human endometrial cycle by expression profiling with respect to receptive status (3, 46) . A diagnostic tool has been developed to identify receptive endometrium using a specific transcriptomics signature in both natural and hormonal replacement therapy cycles (47) . The endometrial receptivity array (ERA) is a customised microarray platform of 238 genes differentially expressed during the menstrual cycle that can identify the WOI of each patient (48) . ERA appears superior to endometrial histology, and results are reproducible in the same patient on the same day of her menstrual cycle up to 40 months later (48) . ERA for WOI detection to schedule embryo transfer in patients with recurrent implantation failure has recently been reported as a novel IVF therapeutic strategy (49) . The proteomic profile of the human endometrium throughout the menstrual cycle has also been studied (50) (51) (52) . However, despite the large amount of information generated, a consensus profile has not been established. Analysis of endometrial secretions (secretomics) is an emerging, noninvasive alternative, since endometrial fluid aspiration in the same treatment cycle does not affect pregnancy rates (53) .
DeCiDuAlizATiOn iS CRiTiCAl FOR PRegnAnCy SuCCeSS
During decidualization in a normal pregnancy in mice, the implanting blastocyst initiates changes in the surrounding stromal cells, inducing stromal proliferation and differentiation into decidual cells (1) . In humans, the initiation of this process (predecidualization) does not require the presence of a blastocyst; however, the process becomes robust with implantation. Predecidualization prepares the endometrium for implantation and appears akin to the extensive stromal cell proliferation with expression of decidual markers seen prior to implantation in mice (1) . Decidualization involves morphogenic, molecular, and vascular modifications that are initiated by estrogen following P 4 priming. Hoxa10 and Hoxa11, critical for patterning during development, are also expressed in the uterus and have crucial roles in decidualization; deletion of these genes produces compromised P 4 signaling and fertility in mice (54) (55) (56) (57) . Morphologically, decidualization is characterized by elongated stromal cells transforming into enlarged round cells with specific ultrastructural modifications. In humans, this transformation is accompanied by the secretion of prolactin (PRL) and insulin-like growth factor binding protein-1 (IGFBP-1) (58) with changes in extracellular matrix proteins such as laminin, type IV collagen, fibronectin, and heparin sulphate proteoglycans (59) (60) (61) .
Proteomic analysis during human decidualization revealed 60 differentially expressed proteins including known markers (cathepsin B) and new potential biomarkers (transglutaminase 2 and peroxiredoxin 4) (59) . Secretomics analysis during this process identified 13 secreted proteins including established (IGFBP-1 and PRL) and novel (MPIF-1 and PECAM-1) markers (61) .
APPROPRiATe TROPhOBlAST inVASiOn iS CRiTiCAl TO PlACenTATiOn
Trophoblast invasion through the maternal decidua induces extracellular matrix (ECM) remodeling regulated by both the trophectoderm and the stroma (62) . Metalloproteinases (MMPs) play key roles in degrading ECM components (63) . MMP-2 and MMP-9 are expressed and secreted by the human endometrium and participate in tissue remodelling during implantation and promote menstruation during normal cycles (64) (65) (66) (67) . Conversely, decidual cells activate the expression of tissue inhibitors of MMPs (TIMPs) and downregulate urokinase plasminogen activator (uPA) (65) . It is thought that TIMPs limit ECM degradation by MMPs during decidualization, restricting embryonic invasion. A balance between these factors is crucial for a successful pregnancy outcome (1, (68) (69) (70) . Aberrant decidual display of ECM components is associated with preeclampsia or restricted intrauterine growth (71, 72) . It was also recently reported that histone acetylation derails the balance of ECM modulators, inhibiting trophoblast invasion (73) .
ADVAnCeS AnD ChAllengeS
Uterine transition through the prereceptive, receptive, and refractory phases is dynamic and rapid. Many genes show overlapping expression spanning more than one phase and/or uterine tissue compartment, making stage-and tissue-specific contributions of particular genes difficult to ascertain with current tools. For example, Bmp2, which is expressed in the stroma during attachment and decidualization, is considered to be critical for decidualization in mice (74, 75) , but its exact mechanism of action is still unknown. Cre recombinase-expressing mouse lines have been used to delete or overexpress floxed genes, but expression of these genes in multiple cell types from the uterus, ovary, and pituitary often limits interpretation of results. Therefore, there is still a need for the development of reproductive tissue-and cell-specific Cre lines. Generation of inducible conditional knockout mouse models could be valuable in addressing stage-specific effects of a gene with overlapping expression patterns. However, the transient and dynamic expression of some genes makes the utility of such inducible systems questionable.
Limited numbers of systems biological approaches-embracing genomics, transcriptomics, proteomics, lipidomics, and metabolomics-have been used to study the intricate and dynamic changes underlying implantation. These studies have produced a wealth of information, but effective assimilation and rigorous validation of the results are lacking, limiting their impact.
Comparative research on implantation across species has become rare in recent years. Studies contrasting different strategies and/or hormonal requirements could help to identify common mechanisms underlying implantation, better understand the causes of female infertility, and improve pregnancy rates. In particular, the transition iii of the uterus from receptive to nonreceptive states requires special attention since the molecular interplay required remains largely unknown and may be critical to extend the WOI during IVF. The complexities of pregnancy necessitate continued basic and clinical research, since aberrant implantation leads to compromised pregnancy outcomes and may even impact the long term health of offspring.
